[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5234
1. Mathews MS, Duma CM, Brant-Zawadzki M, Hasso A, Westhout FD, Klein DJ, Vanhorn D: Extramedullary hematopoeisis within a convexity meningioma. Surg Neurol; 2008 May;69(5):522-5; discussion 525
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hematopoiesis outside the bone marrow is known to occur in patients with severe anemia, leukemia, polycythemia, or myelofibrosis, and in patients affected by chronic poisoning by marrow-toxic substances.
  • A hematoxylin-eosin-stained biopsy specimen showed whorls of tumor cells, diagnostic of a meningioma.
  • Flow cytometric evaluation confirmed the clinical suspicion of an underlying chronic lymphocytic leukemia.

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714768.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR: The BCL-2 family reunion. Mol Cell; 2010 Feb 12;37(3):299-310
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B cell CLL/lymphoma-2 (BCL-2) and its relatives comprise the BCL-2 family of proteins, which were originally characterized with respect to their roles in controlling outer mitochondrial membrane integrity and apoptosis.
  • Here we will discuss the mechanisms and functions of the BCL-2 family in the context of these pathways, highlighting the complex integration and regulation of the BCL-2 family in cell fate decisions.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2009 Nov 13;36(3):355-63 [19917245.001]
  • [Cites] Mol Cell. 2009 Nov 13;36(3):487-99 [19917256.001]
  • [Cites] Mol Cell. 2009 Nov 25;36(4):696-703 [19941828.001]
  • [Cites] Nature. 2010 Jan 7;463(7277):103-7 [20023629.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10892-903 [18281291.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):13123-32 [17337444.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):405-13 [17377525.001]
  • [Cites] Apoptosis. 2007 May;12(5):897-911 [17453159.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):277-87 [17452531.001]
  • [Cites] EMBO J. 2007 May 16;26(10):2527-39 [17446862.001]
  • [Cites] Cell Death Differ. 2007 Jun;14(6):1086-94 [17332775.001]
  • [Cites] Autophagy. 2007 Jul-Aug;3(4):374-6 [17438366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11649-54 [17606912.001]
  • [Cites] Genes Dev. 2007 Aug 1;21(15):1937-48 [17671092.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1057-65 [17721514.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):561-8 [17643073.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19500-5 [18048346.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16202-12 [10821866.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):2060-71 [10950869.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6453-62 [11102440.001]
  • [Cites] Dev Cell. 2001 Oct;1(4):515-25 [11703942.001]
  • [Cites] Dev Cell. 2002 Jan;2(1):55-67 [11782314.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):19-30 [12086884.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):183-92 [12242151.001]
  • [Cites] Cell. 2002 Nov 1;111(3):331-42 [12419244.001]
  • [Cites] J Cell Biol. 2002 Dec 23;159(6):931-8 [12499352.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] Science. 2003 Apr 4;300(5616):135-9 [12624178.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36373-9 [12783892.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]
  • [Cites] Nat Cell Biol. 2004 May;6(5):443-50 [15077116.001]
  • [Cites] Mol Biol Cell. 2004 Nov;15(11):5001-11 [15356267.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Cell. 1989 Apr 7;57(1):79-88 [2649247.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13829-34 [9153240.001]
  • [Cites] J Virol. 1998 Nov;72(11):8586-96 [9765397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):105-10 [15613488.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):393-403 [15694340.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1101-4 [15718471.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Science. 2005 Sep 9;309(5741):1732-5 [16151013.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35742-50 [16115883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17975-80 [16330765.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):97-108 [16493416.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):761-73 [16543146.001]
  • [Cites] Science. 2006 Apr 28;312(5773):572-6 [16645094.001]
  • [Cites] Cancer Cell. 2006 May;9(5):351-65 [16697956.001]
  • [Cites] Cell. 2006 Jul 14;126(1):163-75 [16839884.001]
  • [Cites] Cell. 2006 Jul 14;126(1):177-89 [16839885.001]
  • [Cites] J Cell Biol. 2006 Sep 25;174(7):915-21 [16982799.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7397-408 [17015472.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4738-45 [16966688.001]
  • [Cites] Nature. 2006 Oct 12;443(7112):658-62 [17035996.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1348-58 [17115033.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Science. 2007 Feb 9;315(5813):856-9 [17289999.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • [Cites] Dev Cell. 2008 Feb;14(2):193-204 [18267088.001]
  • [Cites] Nat Immunol. 2008 Apr;9(4):405-14 [18327259.001]
  • [Cites] Trends Cell Biol. 2008 Apr;18(4):157-64 [18314333.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):369-80 [18471982.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1029-36 [18443228.001]
  • [Cites] Mol Biol Cell. 2008 Jun;19(6):2402-12 [18353969.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):678-88 [18570871.001]
  • [Cites] Nature. 2008 Jul 10;454(7201):232-5 [18454133.001]
  • [Cites] J Biol Chem. 2008 Jul 25;283(30):21294-304 [18524770.001]
  • [Cites] Mol Cell. 2008 Aug 22;31(4):557-69 [18691924.001]
  • [Cites] Mol Cell. 2008 Aug 22;31(4):570-85 [18722181.001]
  • [Cites] Cell Death Differ. 2008 Oct;15(10):1564-71 [18551131.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1076-81 [18948948.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):605-10 [19052620.001]
  • [Cites] Cell. 2008 Dec 12;135(6):1074-84 [19062087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20327-32 [19074266.001]
  • [Cites] Mol Cell. 2009 Jan 16;33(1):15-29 [19150424.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):2719-28 [19029119.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1126-32 [19228717.001]
  • [Cites] Nature. 2009 May 21;459(7245):428-32 [19363473.001]
  • [Cites] Autophagy. 2009 Jul;5(5):720-2 [19395874.001]
  • [Cites] Cell Death Differ. 2009 Aug;16(8):1135-45 [19300452.001]
  • [Cites] Science. 2009 Jul 24;325(5939):477-81 [19556461.001]
  • [Cites] Apoptosis. 2009 Aug;14(8):929-34 [19629695.001]
  • [Cites] Nat Cell Biol. 2009 Aug;11(8):958-66 [19578372.001]
  • [Cites] J Cell Biol. 2009 Aug 10;186(3):355-62 [19651893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14397-402 [19706527.001]
  • (PMID = 20159550.001).
  • [ISSN] 1097-4164
  • [Journal-full-title] Molecular cell
  • [ISO-abbreviation] Mol. Cell
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / F32 CA101444; United States / NIAID NIH HHS / AI / R01 AI040646; United States / NIAID NIH HHS / AI / R01 AI040646-16
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Number-of-references] 89
  • [Other-IDs] NLM/ NIHMS337530; NLM/ PMC3222298
  •  go-up   go-down


3. Kumar N, Varma N, Varma S, Malhotra P: Study of diagnostic and prognostic parameters (including flow cytometry) in chronic lymphoproliferative disorders: the Indian perspective. Anal Quant Cytol Histol; 2009 Oct;31(5):296-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of diagnostic and prognostic parameters (including flow cytometry) in chronic lymphoproliferative disorders: the Indian perspective.
  • OBJECTIVE: To assess for chronic lymphoproliferative disorders (CLPD) using several diagnostic and prognostic parameters, including cell morphology, immunologic markers and molecular and cytogenetic investigations, some of which had not been used in the assessment of patients in India.
  • STUDY DESIGN: This prospective study involved the analysis of peripheral blood and bone marrow (BM) aspirate morphology, BM infiltration pattern and lymphoid cell flow cytometry (FCM) in patients with CLPDs.
  • These findings were compared with other disease parameters.
  • RESULTS: Chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL) were the most commonly encountered CLPDs among 91 CLPD patients.
  • Seventy cases were diagnosed as CLL, 14 as HCL and 7 as miscellaneous.
  • Sixty-nine CLL cases showed typical CLL immunophenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701097.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


Advertisement
4. Hogan M, Claffey J, Pampillón C, Tacke M: Synthesis and cytotoxicity studies of new morpholino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs. Med Chem; 2008 Mar;4(2):91-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When these titanocenes were tested against LLC-PK cells, the IC(50) values obtained were of 24, 36, and 41 microM respectively.
  • The most cytotoxic titanocene in this paper (5a) with an IC(50) value of 24 microM is found to be almost ten times less cytotoxic than cis-platin, which showed an IC(50) value of 3.3 microM when tested on the epithelial pig kidney LLC-PK cell line, and approximately 2 times less cytotoxic than its dimethylamino-functionalised analogue.
  • [MeSH-minor] Animals. Cyclopentanes. Inhibitory Concentration 50. LLC-PK1 Cells. Structure-Activity Relationship. Swine

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336326.001).
  • [ISSN] 1573-4064
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclopentanes; 0 / Morpholines; 0 / Organometallic Compounds; 1271-29-0 / titanocene; 19W699IKIE / fulvene
  •  go-up   go-down


5. Nicoloso MS, Kipps TJ, Croce CM, Calin GA: MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol; 2007 Dec;139(5):709-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNAs in the pathogeny of chronic lymphocytic leukaemia.
  • MicroRNAs (miRNAs) have been linked to the initiation and progression of chronic lymphocytic leukaemia (CLL).
  • Recent studies have shown that miRNAs are the main candidates for the elusive class of CLL predisposing genes.
  • These discoveries could be exploited for the development of useful markers for diagnosis and prognosis, as well as for the development of new RNA-based cancer therapies.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. MicroRNAs / genetics. RNA, Neoplasm / genetics
  • [MeSH-minor] Animals. Disease Models, Animal. Gene Deletion. Genetic Predisposition to Disease. Humans. Mice. Mice, Transgenic

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021085.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Neoplasm
  • [Number-of-references] 60
  •  go-up   go-down


6. da Silva R, Saraiva J, de Albuquerque S, Curti C, Donate PM, Bianco TN, Bastos JK, Silva ML: Trypanocidal structure-activity relationship for cis- and trans-methylpluviatolide. Phytochemistry; 2008 Jun;69(9):1890-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the compounds was assessed by the MTT method using LLC-MK2 cells.
  • Trans-methylpluviatolide displayed low toxicity for LLC-MK2 cells, with an IC50 of 6.53 mM.
  • [MeSH-minor] Animals. Cell Line. Macrophages / drug effects. Macrophages / metabolism. Mice. Molecular Structure. Nitric Oxide / biosynthesis. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479721.001).
  • [ISSN] 0031-9422
  • [Journal-full-title] Phytochemistry
  • [ISO-abbreviation] Phytochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lactones; 0 / Lignans; 0 / Trypanocidal Agents; 0 / methylpluviatolide; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


7. Furlan A, Villanova F, Pietrogrande F, Celadin M, Sanzari M, Vianello F: Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro. Leuk Lymphoma; 2010 Jan;51(1):107-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro.
  • Rituximab maintenance therapy provides a significant benefit in patients with indolent B-cell non-Hodgkin lymphoma (NHL).
  • Based on its efficacy in improving response to chemotherapy, the anti-CD20 antibody is currently under evaluation as maintenance therapy also in patients with B-CLL.
  • We evaluated rituximab-mediated cytotoxicity in 10 B-CLL cases pretreated in vitro with non-cytotoxic concentrations of fludarabine.
  • Consistent with the viability assay, we found an increased caspase-3 activity together with activation of caspase-9 in B-CLL cells sensitive to sequential non-cytotoxic fludarabine and rituximab exposure.
  • Non-cytotoxic fludarabine concentrations may sensitize B-CLL cells to rituximab-mediated cytotoxicity via caspase-3 activation.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Caspase 3 / metabolism. Drug Synergism. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Blotting, Western. Caspase 9 / metabolism. Cell Separation. Enzyme Activation. Female. Flow Cytometry. Humans. In Vitro Techniques. Male. Middle Aged. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001234.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


8. Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS: CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. Cytometry B Clin Cytom; 2010;78 Suppl 1:S35-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.
  • BACKGROUND: The pathology and clinical course of patients with CD5+ chronic B-cell lymphoproliferative disorders, excluding those that present with typical chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) or mantle cell lymphoma, (i.e.
  • METHODS: We studied patients with CD5+B-CLPD to (1) more completely define the clinical features and pathology of CD5+B-CLPD, (2) compare these features to patients presenting with typical CLL, and (3) test the hypothesis that a subset of patients with CD5+B-CLPD could have a unique B-cell malignancy.
  • A definitive pathological diagnosis was made in all 61 (27%) CD5+B-CLPD patients with nonbone marrow (BM) biopsy specimens considered adequate for a comprehensive pathological examination.
  • The most common diagnosis among these 61 patients was CLL (44%) followed by the leukemic phase of marginal zone lymphoma (34%), lymphoplasmacytic lymphoma (11%), diffuse large B cell lymphoma (8%), and high-grade B cell lymphoma not otherwise specified (2%).
  • In contrast, among 168 patients without a non-BM tissue biopsy specimen, a specific diagnosis could be made on review of all available data in only 24 (14%) with 144 (86%) remaining "unclassified."
  • CONCLUSIONS: In patients with CD5+B-CLPD, a definitive diagnosis can be made on an adequate non-BM tissue biopsy suggesting that this entity does not include a novel disease.
  • We recommend that all patients with CD5+B-CLPD should have a non-BM tissue biopsy to make a definitive diagnosis prior to initiation of treatment.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Clinical Cytometry Society.
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Leuk Res. 2010 Sep;34(9):1235-8 [20362334.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):655-64 [11710681.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):182-6 [12720133.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Br J Haematol. 1994 Jul;87(3):523-8 [7993792.001]
  • [Cites] Br J Haematol. 1996 Feb;92(2):382-8 [8603004.001]
  • [Cites] Am J Clin Pathol. 1997 Oct;108(4):378-82 [9322589.001]
  • [Cites] Clin Lymphoma. 2005 Mar;5(4):246-9 [15794857.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):36-42 [15982342.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2006-7 [17071467.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2088-95 [17071481.001]
  • [Cites] Am J Hematol. 2008 May;83(5):349-54 [18186522.001]
  • [Cites] Am J Hematol. 2008 May;83(5):347-8 [18383327.001]
  • [Cites] Br J Haematol. 2008 May;141(5):615-21 [18373706.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Mayo Clin Proc. 2008 Jul;83(7):776-85 [18613994.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1325-30 [11571749.001]
  • (PMID = 20568273.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097274-04; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / P50 CA097274-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS222549; NLM/ PMC2943034
  •  go-up   go-down


9. Kaufman M, Limaye SA, Driscoll N, Johnson C, Caramanica A, Lebowicz Y, Patel D, Kohn N, Rai K: A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma; 2009 Jun;50(6):892-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.
  • Auto-immune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP) are known complications of chronic lymphocytic leukemia (CLL).
  • Rituximab, cyclophosphamide and dexamethasone (RCD) effectively target lymphocytes and inhibit autoimmune processes.
  • We reviewed 21 patients with CLL treated for AIHA alone (n = 18), ITP alone (n = 1) or both (n = 2) with the following RCD regimen: rituximab 375 mg/m(2) i.v. infusion given on day 1, cyclophosphamide 750-1000 mg/m(2) i.v. on day 2 and dexamethasone 12 mg day 1-7 given every 3 weeks.
  • Response to treatment was seen in all 20 patients with CLL with AIHA.
  • Nine relapsed patients responded as well.
  • RCD is a safe and effective regimen in the treatment of immune cytopenias associated with CLL.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Purpura, Thrombocytopenic, Idiopathic / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Jun;50(6):863-4 [19455465.001]
  • (PMID = 19391041.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


10. Liu L, Yang C, Herzog C, Seth R, Kaushal GP: Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol; 2010 Jan 15;79(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate the effect of proteasome inhibitors in mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-exposed renal tubular epithelial cells (LLC-PK(1) cells) and in a model of cisplatin nephrotoxicity.
  • Downregulation of Mcl-1 by small interfering RNA promoted Bax activation and cytochrome c and AIF release, suggesting that cisplatin-induced Mcl-1 depletion and associated Bax activation are involved in the release of AIF.
  • [MeSH-minor] Animals. Blotting, Western. Immunoprecipitation. LLC-PK1 Cells. Male. Mice. Mice, Inbred C57BL. Swine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699182.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Novaretti MC, Domingues AE, Manhani R, Pinto EM, Dorlhiac-Llacer PE, Chamone DA: ABO genotyping in leukemia patients reveals new ABO variant alleles. Genet Mol Res; 2008;7(1):87-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABO genotyping in leukemia patients reveals new ABO variant alleles.
  • The aim of the present study was to perform ABO genotyping in patients with leukemia.
  • Blood samples were collected from 108 Brazilian patients with chronic myeloid leukemia (N = 69), chronic lymphoid leukemia (N = 13), acute myeloid leukemia (N = 15), and acute lymphoid leukemia (N = 11).
  • We identified 22 new ABO*variants in the coding region of the ABO gene in 25 individuals with leukemia (23.2%).
  • The majority of ABO variants was detected in O alleles (15/60.0%).
  • Elucidation of the diversity of this gene in leukemia and in other diseases is important for the determination of the effect of changes in an amino acid residue on the specificity and activity of ABO glycosyltransferases and their function.
  • In conclusion, this is the first report of a large number of patients with leukemia genotyped for ABO.
  • The findings of this study indicate that there is a high level of recombinant activity in the ABO gene in leukemia patients, revealing new ABO variants.
  • [MeSH-major] ABO Blood-Group System / genetics. Alleles. Genetic Variation. Leukemia / blood

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273824.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 9007-49-2 / DNA
  •  go-up   go-down


12. Gintowt AA, Germer JJ, Mitchell PS, Yao JD: Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit. J Clin Virol; 2005 Oct;34(2):155-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The current manual sample processing method recommended for use with the TRUGENE HBV Genotyping Kit (TRUGENE HBV; Bayer HealthCare LLC, Tarrytown, NY) is labor-intensive and may be prone to specimen cross-contamination.
  • Performance of TRUGENE HBV used in conjunction with MP sample processing was evaluated further using 22 clinical serum specimens containing low titers of HBV DNA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023890.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


13. Rhyu DY, Kang KS, Sekiya M, Tanaka T, Park JC, Yokozawa T: Active compounds isolated from traditional Chinese prescription Wen-Pi-Tang protecting against peroxynitrite-induced LLC-PK(1) cell damage. Am J Chin Med; 2008;36(4):761-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active compounds isolated from traditional Chinese prescription Wen-Pi-Tang protecting against peroxynitrite-induced LLC-PK(1) cell damage.
  • Wen-Pi-Tang, a traditional Chinese prescription, has been widely used for the treatment of patients with moderate chronic renal failure in China.
  • Although the protective effect of Wen-Pi-Tang on peroxynitrite (ONOO(-))-induced renal tubular epithelial LLC-PK(1) cell damage was elucidated in our previous research, the active components of Wen-Pi-Tang have not yet been fully clarified.
  • Therefore, the major bioactivity of Wen-Pi-Tang against ONOO(-)-induced cytotoxicity in LLC-PK(1) cells was thought to be mediated by (+)-catechin.
  • Although we cannot disregard the synergetic effect of various components in Wen-Pi-Tang, (+)-catechin is a major active compound protecting against ONOO(-)-induced LLC-PK(1) cell damage and may be used as an index to qualify the ONOO(-)-inhibitory activity of Wen-Pi-Tang extract.
  • [MeSH-minor] Animals. Cell Line. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Free Radicals / metabolism. Molsidomine / analogs & derivatives. Molsidomine / pharmacology. Nitric Oxide Donors / pharmacology. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711772.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Free Radicals; 0 / Nitric Oxide Donors; 0 / wen-pi-tang; 14691-52-2 / Peroxynitrous Acid; 5O5U71P6VQ / linsidomine; 8R1V1STN48 / Catechin; D46583G77X / Molsidomine
  •  go-up   go-down


14. Mailloux AW, Clark AM, Young MR: NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells. Int J Cancer; 2010 Dec 1;127(11):2598-611
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies demonstrated that NK-dependant increases in CCL22 secretion selectively recruit Tregs toward murine lungs bearing Lewis Lung Carcinoma (LLC).
  • To extend the in vitro studies, the present studies utilized in vivo depletion of NK cells to ascertain the contribution of NK-derived CCL22 toward total CCL22 and subsequent Treg levels in both normal and LLC-bearing lungs.
  • However, NK depletion had the unexpected effect of increasing both CCL22 secretion and Treg levels in the lungs of NK-depleted LLC-bearing mice.
  • Flow cytometry and a series of both immunomagnetic and FACS isolations were used to identify the CCL22-producing cellular fractions in LLC-bearing lungs.
  • A novel CD11b(+)CD11c(+) cell population was identified that accumulates in large numbers in NK-depleted LLC-bearing lung tissue.
  • These CD11b(+)CD11c(+) cells secreted large amounts of CCL22 that may overcompensate for the loss of NK-derived CCL22 in the lungs of NK-depleted LLC-bearing mice.
  • Taken together, these data suggest that NK cells play both a positive and negative role in the regulation of CCL22 secretion and, in turn, the recruitment of Tregs toward LLC-bearing lungs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Feb 21;191(4):661-8 [10684858.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):2753-65 [19234170.001]
  • [Cites] Int Immunol. 2001 Apr;13(4):459-63 [11282985.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):531-7 [11310838.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2342-8 [12805336.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):89-98 [15036232.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Reticuloendothel Soc. 1979 Jun;25(6):623-33 [385867.001]
  • [Cites] Boll Ist Sieroter Milan. 1985;64(1):25-34 [3859302.001]
  • [Cites] J Natl Cancer Inst. 1986 Apr;76(4):745-50 [3457207.001]
  • [Cites] J Natl Cancer Inst. 1986 Dec;77(6):1255-60 [3491925.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):275-82 [9568645.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):5027-38 [9794440.001]
  • [Cites] Diabetes. 2005 Feb;54(2):434-42 [15677501.001]
  • [Cites] J Immunol. 2009 Dec 15;183(12):8044-53 [19933856.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5211-20 [15958566.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6169-76 [16237114.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5716-22 [16740709.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] Blood. 2008 Jan 15;111(2):761-6 [17967942.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2286-93 [18224687.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1733-41 [11238115.001]
  • (PMID = 20198623.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA8566; United States / NIDCR NIH HHS / DE / R01 DE018168-02; United States / NCI NIH HHS / CA / 1R01CA128837; United States / NCI NIH HHS / CA / R01 CA085266-06; United States / NCI NIH HHS / CA / R01 CA085266; United States / NIDCR NIH HHS / DE / R01DE018168; United States / NIDCR NIH HHS / DE / R01 DE018168; United States / NCI NIH HHS / CA / CA128837-01A2; United States / NCI NIH HHS / CA / R01 CA128837; United States / NCI NIH HHS / CA / R01 CA128837-01A2; United States / NIDCR NIH HHS / DE / DE018168-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD11c; 0 / CCL22 protein, human; 0 / Chemokine CCL22; 37758-47-7 / G(M1) Ganglioside; 71012-19-6 / asialo GM1 ganglioside
  • [Other-IDs] NLM/ NIHMS189166; NLM/ PMC2947555
  •  go-up   go-down


15. Coscia G, Vaccara E, Corvisiero R, Cavazzani P, Ruggieri FG, Taccini G: Fractionated stereotactic radiotherapy: a method to evaluate geometric and dosimetric uncertainties using radiochromic films. Med Phys; 2009 Jul;36(7):2870-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The comparison between the dose distributions measured on films and computed by TPS, after a precise image registration procedure performed by a commercial piece of software (FILMQA, 3cognition LLC (Division of ISP), Wayne, NJ), allowed the authors to measure the repositioning errors, obtaining about 0.5 mm in case of central spherical PTV and about 1.5 mm in case of peripheral irregular PTV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673186.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Reid-Nicholson M, Kavuri S, Ustun C, Crawford J, Nayak-Kapoor A, Ramalingam P: Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation. Cancer; 2008 Oct 25;114(5):333-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that was once believed to occur primarily in the oral cavity of human immunodeficiency virus-positive individuals.
  • The presence of the following was evaluated: cellularity, plasmablastic cells, background necrosis (BN), single-cell necrosis (SCN), lymphoglandular bodies (LGB), tingible-body macrophages (TBM), 3-dimensional clusters/sheets, and cytoplasmic vacuoles.
  • Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma.
  • However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683216.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Amagase H, Nance DM: A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi. J Altern Complement Med; 2008 May;14(4):403-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) Juice, GoChi.
  • BACKGROUND: This randomized, double-blind, placebo-controlled clinical trial is the first study reported from outside China that has examined the general effects of the orally consumed goji berry, Lycium barbarum, as a standardized juice (GoChi; FreeLife International LLC, Phoenix, AZ) to healthy adults for 14 days.
  • METHODS: Based upon the medicinal properties of Lycium barbarum in traditional Asian medicine, we examined by questionnaire subjective ratings (0-5) of general feelings of well-being, neurologic/psychologic traits, gastrointestinal, musculoskeletal, and cardiovascular complaints as well as any adverse effects.
  • CONCLUSIONS: These results clearly indicate that daily consumption of GoChi for 14 days increases subjective feelings of general well-being, and improves neurologic/psychologic performance and gastrointestinal functions.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447631.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 0 / Plant Extracts
  •  go-up   go-down


18. John R, Liao K, Lietz K, Kamdar F, Colvin-Adams M, Boyle A, Miller L, Joyce L: Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg; 2007 Aug;134(2):351-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We review our experience with the use of the CentriMag (Levitronix LLC, Waltham, Mass) circulatory support system in such patients whose neurologic status was uncertain.
  • Thus, for our 12 study patients, long-term survival was 75% at 1 month and 62.5% at 1 year.
  • By using this strategy, we avoided the urgent placement of expensive long-term ventricular assist devices in hemodynamically unstable patients with multisystem organ failure whose neurologic status was uncertain until end-organ recovery and excellent hemodynamic stability were achieved with the relatively inexpensive short-term CentriMag circulatory support system.
  • [MeSH-minor] Acute Disease. Analysis of Variance. Decision Making. Heart Transplantation / statistics & numerical data. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Cardiovasc Surg. 2008 Mar;135(3):717; author reply 717-8 [18329513.001]
  • (PMID = 17662772.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Peeters MY, Prins SA, Knibbe CA, Dejongh J, Mathôt RA, Warris C, van Schaik RH, Tibboel D, Danhof M: Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology; 2006 Dec;105(6):1135-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Population pharmacokinetic and pharmacodynamic modeling was performed using NONMEM V (GloboMax LLC, Hanover, MD).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Midazolam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122576.001).
  • [ISSN] 0003-3022
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; R60L0SM5BC / Midazolam
  •  go-up   go-down


20. Goldenberg MM: Pharmaceutical approval update. P T; 2008 May;33(5):299-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topics include bendamustine (Treanda) for chronic lymphocytic leukemia, hepatitis B immune globulin (HepaGam B) to prevent hepatitis B infection following liver transplantation, and a fibrin sealant (Artiss) used in skin graft surgery for burn patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561795.001).
  • [ISSN] 1052-1372
  • [Journal-full-title] P & T : a peer-reviewed journal for formulary management
  • [ISO-abbreviation] P T
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2683604
  •  go-up   go-down


21. Seyfried I, Hofbauer S, Stoecher M, Greil R, Tinhofer I: SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a. Blood; 2008 Sep 1;112(5):2168; author reply 2169
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.
  • [MeSH-major] Imidazoles / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Proto-Oncogene Proteins c-mdm2 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2008 Feb 1;111(3):1584-93 [17971485.001]
  • (PMID = 18725577.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Imidazoles; 0 / Piperazines; 0 / nutlin 3; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


22. Yağci M, Akar I, Sucak GT, Haznedar R: GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes. Leuk Res; 2005 Jul;29(7):735-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes.
  • CD20 antigen expression in B-chronic lymphocytic leukemia (B-CLL) is at significantly lower levels than in non-Hodgkins lymphoma, which may affect the degree of anti-CD20 antibody binding.
  • Low density of CD20 expression on malignant cells may explain the lower response rates to anti-CD20 monoclonal antibody, observed in B-CLL.
  • In this study, we examined the influence of granulocyte macrophage-colony stimulating factor (GM-CSF) on the expression level of CD20 antigen and percent of cells expressing CD20 antigen on B-CLL lymphocytes, in vivo.
  • Strategies other than GM-CSF priming needs to be evaluated in order to increase the efficacy of anti-CD20 monoclonal antibodies in B-CLL.
  • [MeSH-major] Antigens, CD20 / genetics. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • [MeSH-minor] Animals. Antigens, CD / genetics. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. Humans. Lymphoma, Non-Hodgkin / immunology. Mice

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15927668.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


23. Ruddy KJ, Wu D, Brown JR: Pseudohyperkalemia in chronic lymphocytic leukemia. J Clin Oncol; 2008 Jun 1;26(16):2781-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudohyperkalemia in chronic lymphocytic leukemia.
  • [MeSH-major] Hyperkalemia / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509189.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One; 2009;4(11):e7826
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.
  • BACKGROUND: Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia.
  • The role of miRNAs in pediatric leukemia still needs to be established.
  • The purpose of this study was to investigate the aberrantly expressed miRNAs in pediatric acute leukemia and demonstrate miRNA patterns that are pediatric-specific and prognostic parameter-associated.
  • The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3 and M2 patients, respectively.
  • CONCLUSIONS/SIGNIFICANCE: There are existing pediatric-associated and prognostic parameter-associated miRNAs that are independent of cell lineage and could provide therapeutic direction for individual risk-adapted therapy for pediatric leukemia patients.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Leukemia / diagnosis. Leukemia / pathology. MicroRNAs

  • MedlinePlus Health Information. consumer health - Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] J Pediatr (Rio J). 2003 Mar-Apr;79(2):149-58 [14502336.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):167-73 [16616063.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2825-32 [18089852.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Dev Biol. 1999 Dec 15;216(2):671-80 [10642801.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):179-81 [12525506.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • (PMID = 19915715.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2773830
  •  go-up   go-down


25. Sweeney N, Gallagher WM, Müller-Bunz H, Pampillón C, Strohfeldt K, Tacke M: Heteroaryl substituted titanocenes as potential anti-cancer drugs. J Inorg Biochem; 2006 Sep;100(9):1479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When titanocenes 3a-c were tested against pig kidney (LLC-PK) cells inhibitory concentrations (IC(50)) of 1.6x10(-4)M, 1.5x10(-4)M and 9.1x10(-4)M, respectively, were observed.
  • These values represent improved cytotoxicity against LLC-PK, when compared to their corresponding ansa substituted analogues and also in comparison to unsubstituted titanocene dichloride.
  • [MeSH-minor] Animals. Cell Line. Cell Survival. Drug Evaluation, Preclinical. Molecular Conformation. Molecular Structure. Swine

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764931.001).
  • [ISSN] 0162-0134
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organometallic Compounds; 1271-29-0 / titanocene
  •  go-up   go-down


26. Salerno E, Yuan Y, Scaglione BJ, Marti G, Jankovic A, Mazzella F, Laurindo MF, Despres D, Baskar S, Rader C, Raveche E: The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia. Cytometry B Clin Cytom; 2010;78 Suppl 1:S98-109
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.
  • BACKGROUND: Similar to a subset of human patients who progress from monoclonal B lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL), New Zealand Black (NZB) mice have an age-associated progression to CLL.
  • The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16.
  • METHODS: Spleens of aging NZB were analyzed for the presence of B-1 cells via flow cytometry and for the presence of a side population (SP) via the ability of cells to exclude Hoechst 33342 dye.
  • The SP was assayed for the presence of hyperdiploid B-1 clones and for the ability to differentiate into B-1 cells in vitro and transfer disease in vivo.
  • RESULTS: Aging NZB mice develop a B-1 expansion and clonal development that evolves from MBL into CLL.
  • Although the SP did contain increased cells with stem cell markers, they lacked malignant B-1 cells and did not transfer disease in vivo.
  • CONCLUSION: NZB serve as an excellent model for studying the development and progression of age-associated CLL.
  • NZB SP cells do not seem to contain cancer stem cells, but rather the B-1 stem cell.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Clinical Cytometry Society.
  • [Cites] Nat Med. 2008 Nov;14(11):1271-7 [18931683.001]
  • [Cites] Nucleic Acids Res. 2008 Sep;36(16):5391-404 [18701644.001]
  • [Cites] Cytometry A. 2009 Jan;75(1):14-24 [19023891.001]
  • [Cites] Phytother Res. 2009 Jun;23(6):868-73 [19107739.001]
  • [Cites] Mol Cancer Ther. 2009 Sep;8(9):2684-92 [19723889.001]
  • [Cites] Mol Cancer. 2009;8:106 [19922650.001]
  • [Cites] Cytometry A. 2010 Jan;77(1):6-10 [20024907.001]
  • [Cites] Leukemia. 2010 Jan;24(1):133-40 [19946263.001]
  • [Cites] Nature. 2010 Jan 28;463(7280):540-4 [20023630.001]
  • [Cites] Cytometry B Clin Cytom. 2010;78 Suppl 1:S10-8 [20839330.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6640-8 [11559527.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):99-108 [11699227.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Semin Hematol. 2004 Jul;41(3):201-6 [15269880.001]
  • [Cites] Cancer Res. 1992 Jan 15;52(2):437-43 [1370214.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1869-80 [8046247.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1850-7 [7535590.001]
  • [Cites] Cell Immunol. 1996 May 1;169(2):196-207 [8620547.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] J Autoimmun. 1996 Apr;9(2):207-10 [8738964.001]
  • [Cites] J Clin Invest. 1996 Oct 15;98(8):1788-93 [8878429.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2463-73 [9395242.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):27595-603 [15932881.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] J Surg Res. 2006 Jan;130(1):124-35 [16154142.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):195-201 [16616066.001]
  • [Cites] Blood. 2006 May 15;107(10):4109-14 [16439685.001]
  • [Cites] Cell. 2006 Jun 2;125(5):887-901 [16751099.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2240-52 [17242205.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5079-86 [17351108.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):385-97 [17707828.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):701-8 [18021084.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):709-16 [18021085.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):645-57 [17941951.001]
  • [Cites] Autoimmun Rev. 2007 Dec;7(2):127-31 [18035322.001]
  • [Cites] Cell Res. 2008 May;18(5):549-57 [18379589.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3059-67 [19096043.001]
  • (PMID = 20839343.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129826-01A2; United States / NCI NIH HHS / CA / R01 CA129826; United States / NCI NIH HHS / CA / R01 CA129826-01A2; United States / NCI NIH HHS / CA / R01CA129826
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Piperazines; 0 / nutlin 1
  • [Other-IDs] NLM/ NIHMS241534; NLM/ PMC2963456
  •  go-up   go-down


27. Sabattini E, Orduz R, Campidelli C, Zinzani PL, Callea V, Zupo S, Cutrona G, Morabito F, Ferrarini M, Pileri S: B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. J Clin Pathol; 2007 Jun;60(6):627-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.
  • BACKGROUND: The course of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) partly depends on the mutational status of the variable region of immunoglobulin heavy chain genes (IgV(H)), which defines two subgroups of tumours: mutated and unmutated.
  • METHODS: 26 patients with CLL/SLL detected on BMB and with known IgV(H) mutational status were selected.
  • ZAP70 was determined by immunohistochemistry (IHC) comparing three antibodies from different sources (Upstate, Cell Signaling, Santa Cruz, California, USA) and two different methods (APAAP and EnVision(+)).
  • RESULTS: ZAP70 determination on BMB specimens turned out to be easily feasible with routine procedures with reagents from Upstate and Cell Signaling.
  • CONCLUSIONS: The study confirms the role of ZAP70 as a possible surrogate of mutational status and emphasises its application in routine diagnostics; it discloses a small subset of discordant cases (mutated/ZAP70 weakly positive) that clinically cluster with the more favourable forms.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] Am J Clin Pathol. 1996 Oct;106(4):457-61 [8853032.001]
  • [Cites] Blood. 2001 Jul 1;98(1):181-6 [11418478.001]
  • [Cites] Leuk Res. 2001 Nov;25(11):927-32 [11597727.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):142-50 [11841407.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]
  • [Cites] Ann Hematol. 2002 Jun;81(6):299-303 [12107557.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Eur J Haematol. 2003 Jan;70(1):53-9 [12631259.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:153-75 [14633781.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):105-11 [14726163.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):455-62 [15160906.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):954-61 [15133473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):69-72 [15325098.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii [15325699.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):807-26, viii [15325700.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):827-48, viii [15325701.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2037-45 [15370248.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] Br J Haematol. 1999 May;105(2):394-401 [10233410.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Pathol. 2005 Mar;205(4):507-13 [15685592.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Leukemia. 2005 May;19(5):750-8 [15759031.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1018-24 [15800671.001]
  • [Cites] Cell. 1992 Nov 13;71(4):649-62 [1423621.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 16916999.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  • [Other-IDs] NLM/ PMC1955054
  •  go-up   go-down


28. Bogner C, Sandherr M, Perker M, Weick K, Ringshausen I, Peschel C, Decker T: Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann Hematol; 2006 Jul;85(7):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.
  • The clinical course of chronic lymphocytic leukemia is variable.
  • While some patients have indolent disease, others require aggressive treatment within a short time after diagnosis.
  • Differences in the expression of proteins regulating cell cycle and apoptosis may be responsible for the heterogeneous course of the disease.
  • Recently, protein ZAP 70 [zeta-chain (T-cell receptor) associated protein kinase 70 kDa] has been found to be differentially expressed within two biologic subgroups, characterized by the presence or absence of somatic mutations in specific immunoglobulin heavy-chain variable region genes.
  • In the present work, we analyzed highly purified B-CLL cells from 60 patients for ZAP 70 expression and the expression of cyclin E, bcl-2, bax, and mcl-1 as well as the ratios of bcl-2/bax and mcl-1/bax.
  • We conclude that higher cyclin E expression in samples of ZAP 70-positive patients may reflect a larger proliferating compartment in vivo compared to ZAP 70-negative patients and that cyclin E may add prognostic information in this context for patients with B-CLL.
  • [MeSH-major] Cyclin E / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasm Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. ZAP-70 Protein-Tyrosine Kinase / metabolism. bcl-2-Associated X Protein / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Myeloid Cell Leukemia Sequence 1 Protein. Neoplasm Staging. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538501.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclin E; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


29. Flezar MS, Prevodnik VK, Kirbis IS, Strojan P: Cutaneous squamous cell carcinoma metastatic to chronic lymphocytic leukaemia: diagnostic potential of fine needle aspiration cytology. Cytopathology; 2006 Oct;17(5):288-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma metastatic to chronic lymphocytic leukaemia: diagnostic potential of fine needle aspiration cytology.
  • OBJECTIVE: The phenomenon of cancer-to-cancer metastasis of cutaneous squamous cell carcinoma (SCC) and chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) is a rare event and only occasionally documented in the medical literature.
  • METHODS: Two patients with SCC of the skin that were previously treated for CLL are presented.
  • In addition, the literature on cutaneous SCC metastatic to CLL/SLL with special emphasis on the role of FNAC in this specific clinical situation was reviewed.
  • RESULTS: On examination of the FNAC smear, cancer-to-cancer metastasis of cutaneous SCC to lymph node replaced by CLL was found.
  • In one of the patients, light microscopy examination of the smear was complemented by immunostaining of atypical cells with cytokeratin antibodies and immunophenotyping of lymphoid cells by flow cytometry.
  • In addition to our two patients, nine cases of cutaneous SCC metastatic to CLL/SLL have been reported in the literature, and in only one was the diagnosis made by FNAC.
  • CONCLUSION: FNAC supported by ancillary immunocytological techniques could also be used in diagnosis of specific clinical situations such as cancer-to-cancer metastasis of the tandem of SCC-CLL/SLL.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Second Primary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Fatal Outcome. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961658.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM: Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res; 2006 Dec 15;66(24):11590-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
  • B-cell chronic lymphocytic leukemia (B-CLL) is the most common human leukemia in the world.
  • Deregulation of the TCL1 oncogene is a causal event in the pathogenesis of the aggressive form of this disease as was verified by using animal models.
  • To study the mechanism of Tcl1 regulation in CLL, we carried out microRNA expression profiling of three types of CLL: indolent CLL, aggressive CLL, and aggressive CLL showing 11q deletion.
  • We identified distinct microRNA signatures corresponding to each group of CLL.
  • We further determined that Tcl1 expression is regulated by miR-29 and miR-181, two microRNAs differentially expressed in CLL.
  • Expression levels of miR-29 and miR-181 generally inversely correlated with Tcl1 expression in the CLL samples we examined.
  • Our results suggest that Tcl1 expression in CLL is, at least in part, regulated by miR-29 and miR-181 and that these microRNAs may be candidates for therapeutic agents in CLLs overexpressing Tcl1.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. MicroRNAs / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178851.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA81534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN29 microRNA, rat; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


31. Quijano S, López A, Rasillo A, Barrena S, Luz Sánchez M, Flores J, Fernández C, Sayagués JM, Osuna CS, Fernández N, González M, Giraldo P, Giralt M, Pérez MC, Martin-Antoran JM, Gutiérrez O, Perdiguer L, Díaz Mediavilla J, González Silva M, Asensio Del Rio A, Cerveró C, Guerra JL, Butrón R, García Mdel C, Almeida J, Orfao A: Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood; 2008 May 15;111(10):5130-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients.
  • Limited knowledge exists about the impact of specific genetic abnormalities on the proliferation of neoplastic B cells from chronic lymphoproliferative disorders (B-CLPDs).
  • Here we analyze the impact of cytogenetic abnormalities on the proliferation of neoplastic B cells in 432 B-CLPD patients, grouped according to diagnosis and site of sampling, versus their normal counterparts.
  • Overall, proliferation of neoplastic B cells highly varied among the different B-CLPD subtypes, the greatest numbers of proliferating cells being identified in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).
  • Compared with normal B cells, neoplastic B-CLPD cells showed significantly increased S + G(2)/M-phase values in mantle cell lymphoma (MCL), B-chronic lymphocytic leukemia (B-CLL), BL, and some DLBCL cases.
  • Conversely, decreased proliferation was observed in follicular lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), and some DLBCL patients; hairy cell leukemia, splenic marginal zone, and MALT-lymphoma patients showed S + G(2)/M phase values similar to normal mature B lymphocytes from LN.
  • Interestingly, in B-CLL and MCL significantly higher percentages of S + G(2)/M cells were detected in BM versus PB and in LN versus BM and PB samples, respectively.
  • In turn, presence of 14q32.3 gene rearrangements and DNA aneuploidy, was associated with a higher percentage of S + G(2)/M-phase cells among LPL/WM and B-CLL cases, respectively.
  • [MeSH-major] B-Lymphocytes / pathology. Cell Proliferation. Chromosome Aberrations. Lymphoproliferative Disorders / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337555.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L, Manji HK: The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci; 2005 May 4;25(18):4493-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers.
  • Increasing data suggest that impairments of cellular plasticity/resilience underlie the pathophysiology of bipolar disorder.
  • A series of microarray studies with validating criteria have recently revealed a common, novel target for the long-term actions of the structurally highly dissimilar mood stabilizers lithium and valproate: BAG-1 [BCL-2 (B-cell CLL/lymphoma 2)-associated athanogene].
  • Chronic administration of both agents at therapeutic doses increased the expression of BAG-1 in rat hippocampus.
  • Furthermore, these findings were validated at the protein level, and the effects were seen in a time frame consistent with therapeutic effects and were specific for mood stabilizers.
  • Furthermore, small interfering RNA studies showed that these inhibitory effects on GR activity were mediated, at least in part, through BAG-1.
  • The observation that BAG-1 inhibits glucocorticoid activation suggests that mood stabilizers may counteract the deleterious effects of hypercortisolemia seen in bipolar disorder by upregulating BAG-1.
  • Additionally, these studies suggest that regulation of GR-mediated plasticity may play a role in the treatment of bipolar disorder and raise the possibility that agents affecting BAG-1 more directly may represent novel therapies for this devastating illness.
  • [MeSH-minor] Alkaline Phosphatase / genetics. Alkaline Phosphatase / metabolism. Animals. Behavior, Animal. Blotting, Western / methods. Cell Line, Tumor. Dexamethasone / pharmacology. Dose-Response Relationship, Drug. Drug Interactions. Gene Expression / drug effects. Humans. Immunohistochemistry / methods. Indoles / metabolism. Male. Molecular Weight. Neuroblastoma. RNA, Small Interfering / pharmacology. Rats. Rats, Wistar. Receptors, Glucocorticoid / metabolism. Time Factors. Transfection / methods

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15872096.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimanic Agents; 0 / BCL2-associated athanogene 1 protein; 0 / DNA-Binding Proteins; 0 / Indoles; 0 / RNA, Small Interfering; 0 / Receptors, Glucocorticoid; 0 / Transcription Factors; 47165-04-8 / DAPI; 614OI1Z5WI / Valproic Acid; 7S5I7G3JQL / Dexamethasone; 9FN79X2M3F / Lithium; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


33. Nunes P, Hasler U, McKee M, Lu HA, Bouley R, Brown D: A fluorimetry-based ssYFP secretion assay to monitor vasopressin-induced exocytosis in LLC-PK1 cells expressing aquaporin-2. Am J Physiol Cell Physiol; 2008 Dec;295(6):C1476-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A fluorimetry-based ssYFP secretion assay to monitor vasopressin-induced exocytosis in LLC-PK1 cells expressing aquaporin-2.
  • Vasopressin (VP)-induced exocytosis was dissected in native and aquaporin-2 (AQP2)-expressing renal LLC-PK(1) cells by a fluorimetric exocytosis assay based on soluble secreted yellow fluorescent protein (ssYFP).
  • Fluorimetry and Western blot analysis demonstrated similar constitutive ssYFP secretion in native LLC-PK(1) and AQP2-expressing cells.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2005 Jun;288(6):F1103-12 [15644488.001]
  • [Cites] J Biol Chem. 2008 Sep 26;283(39):26643-61 [18664568.001]
  • [Cites] Mol Cell Proteomics. 2005 Aug;4(8):1095-106 [15905145.001]
  • [Cites] Histochem Cell Biol. 2005 Jul;124(1):1-12 [16049696.001]
  • [Cites] J Am Soc Nephrol. 2005 Oct;16(10):2881-9 [16093449.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1113-25 [16186257.001]
  • [Cites] Traffic. 2005 Dec;6(12):1142-56 [16262725.001]
  • [Cites] Nephrol Dial Transplant. 2000;15 Suppl 6:21-2 [11143977.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Dec;281(6):F1092-101 [11704560.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):205-44 [11773613.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10379-86 [11782489.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Jun;282(6):F998-1011 [11997316.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):1101-7 [12374804.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):88-93 [12524527.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 May;284(5):F893-901 [12676734.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Oct;285(4):C750-62 [12801889.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Feb;286(2):F233-43 [14519593.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32 [15040445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13368-73 [15326289.001]
  • [Cites] Mol Cell Biol. 1985 Dec;5(12):3610-6 [3915782.001]
  • [Cites] Am J Physiol. 1993 Aug;265(2 Pt 2):F214-24 [8396343.001]
  • [Cites] Experientia. 1994 Nov 30;50(11-12):1012-20 [7988659.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7212-6 [7543677.001]
  • [Cites] EMBO J. 1996 Feb 1;15(3):510-9 [8599934.001]
  • [Cites] J Biol Chem. 1997 Jun 6;272(23):14800-4 [9169447.001]
  • [Cites] Am J Physiol. 1997 Jun;272(6 Pt 2):F817-22 [9227644.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Feb;278(2):F317-26 [10662736.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Mar;278(3):F388-94 [10710543.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F29-42 [10644653.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 11):1985-92 [10806109.001]
  • [Cites] J Clin Invest. 2000 Nov;106(9):1115-26 [11067864.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36839-46 [10973964.001]
  • [Cites] Plant Cell Physiol. 2000 Sep;41(9):993-1001 [11100771.001]
  • [Cites] Nature. 1997 Sep 4;389(6646):81-5 [9288971.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):133-42 [9352218.001]
  • [Cites] Curr Opin Neurobiol. 1997 Oct;7(5):631-9 [9384543.001]
  • [Cites] J Membr Biol. 1998 Jan 15;161(2):141-9 [9435270.001]
  • [Cites] Biochem J. 1998 Apr 15;331 ( Pt 2):669-75 [9531511.001]
  • [Cites] J Cell Biol. 1998 Dec 14;143(6):1485-503 [9852146.001]
  • [Cites] J Am Soc Nephrol. 1999 Jul;10(7):1416-29 [10405197.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46969-80 [15319442.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 May;288(5):F930-8 [15625084.001]
  • [Cites] Endocrinology. 2005 Dec;146(12):5063-70 [16150901.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jan;290(1):F177-87 [15985652.001]
  • [Cites] Biol Cell. 2006 Apr;98(4):215-32 [16563128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7159-64 [16641100.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1276-86 [16418206.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jul;291(1):F246-53 [16449354.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Oct;291(4):F882-90 [16684923.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:439-55 [16824007.001]
  • [Cites] Traffic. 2007 Feb;8(2):110-23 [17156409.001]
  • [Cites] PLoS Comput Biol. 2007 Mar 23;3(3):e57 [17381238.001]
  • [Cites] Nat Rev Genet. 2007 Jul;8(7):533-43 [17572691.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1129-38 [17626240.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28721-32 [17636261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16696-701 [17940053.001]
  • [Cites] Neuron. 2007 Nov 21;56(4):657-69 [18031683.001]
  • [Cites] Semin Nephrol. 2008 May;28(3):266-78 [18519087.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2008 Sep;17(5):491-8 [18695390.001]
  • [Cites] J Cell Biol. 2008 Aug 11;182(3):587-601 [18678705.001]
  • [Cites] J Am Soc Nephrol. 2005 Jun;16(6):1571-82 [15843469.001]
  • (PMID = 18799651.001).
  • [ISSN] 0363-6143
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK-38452; United States / NIDDK NIH HHS / DK / DK-43341; United States / NIDDK NIH HHS / DK / DK-57521; United States / NIDDK NIH HHS / DK / K08 DK-075940-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aquaporin 2; 0 / Luminescent Proteins; 11000-17-2 / Vasopressins
  • [Other-IDs] NLM/ PMC2603565
  •  go-up   go-down


34. Mayr C, Kofler DM, Büning H, Bund D, Hallek M, Wendtner CM: Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood; 2005 Nov 1;106(9):3223-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
  • Several features of chronic lymphocytic leukemia (CLL) suggest that immune-based strategies may have therapeutic potential.
  • A promising approach is provided by the transduction of CLL cells with CD40 ligand (CD40L) by viral vectors to enhance their immunogenicity.
  • We compared the antigen-presenting capacity of CD40L-transduced CLL cells with mock-transduced or CD40L-stimulated CLL cells (CD40-CLL).
  • A significantly higher number of T cells could be expanded using CD40L-transduced CLL cells as antigen-presenting cells (APCs) compared with the control group (P = .008).
  • Using 5 different CLL-associated tumor antigens, including fibromodulin, MDM2 (murine double minute 2), survivin, p53, and KW-13, we show in interferon-gamma (IFN-gamma) enzyme-linked immunospot (ELISPOT) assays after 35 days of in vitro culture that the number of antigen-specific autologous T cells was also significantly higher when CD40L-transduced CLL cells were used as APCs (P < .001).
  • Thus, CD40L-transduced CLL cells are able to induce an antigen-specific T-cell response and might be superior to CD40-CLL cells for immune-based therapeutic strategies in CLL.
  • [MeSH-major] CD40 Ligand / immunology. CD40 Ligand / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. T-Lymphocytes / immunology. T-Lymphocytes / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Proliferation. Humans. Interferon-gamma / metabolism. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014560.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 147205-72-9 / CD40 Ligand; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


35. Abbasi F, Longo NS, Lipsky PE, Raveche E, Schleinitz TA, Stetler-Stevenson M, Caporaso N, Marti G: B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred. Br J Haematol; 2007 Dec;139(5):820-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred.
  • Monoclonal B cell lymphocytosis (MBL) was detected in four unaffected first-degree relatives (FDR) in a familial chronic lymphocytic leukaemia (CLL) kindred.
  • Single cell PCR of flow cytometric sorted kappa(+) cells combined with Ig kappa light chain gene sequencing revealed further evidence of monoclonality in two of these individuals.
  • The B-cell repertoire in unaffected FDR in familial CLL offers a new area to investigate the interface between the immune system and lymphoid neoplasm.
  • [MeSH-major] B-Lymphocytes. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphocytosis / genetics. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Antigens, CD5 / blood. Female. Flow Cytometry / methods. Follow-Up Studies. Gene Rearrangement, B-Lymphocyte. Genes, Immunoglobulin Heavy Chain. Genes, Immunoglobulin Light Chain. Genetic Predisposition to Disease. Humans. Male. Mutation. Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941936.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


36. Karakosta M, Tsakiridou A, Korantzis I, Manola KN: Deletion of 5q as a rare abnormality in chronic lymphocytic leukemia. Cancer Genet Cytogenet; 2010 Jul 15;200(2):175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion of 5q as a rare abnormality in chronic lymphocytic leukemia.
  • Deletions of the long arm of chromosome 5 [del(5q)] are frequent chromosome aberrations with known prognosis in myelodysplastic syndromes and acute myeloid leukemia (AML).
  • However, in chronic lymphocytic leukemia (CLL), they are rare and have been reported only as karyotypic results without known prognosis.
  • In the present study, we report a novel conventional and molecular cytogenetic study of two CLL patients carrying interstitial del(5q) in order to contribute to the identification of rare recurrent aberrations and their prognostic impact in CLL.
  • Karyotypic and fluorescence in situ hybridization analysis that used probes for the most common aberrations of CLL demonstrated that del(5q) was the sole chromosome abnormality in both patients at the time of diagnosis.
  • Both patients had disease that was still staged as Binet A at 28 and 18 months after diagnosis, respectively, without receiving any therapy because of their good clinical condition.
  • Therefore, it could be suggested that del(5q) may not be associated with an adverse prognosis in CLL and is not related with therapy-induced chromosome changes.
  • Further studies are required to elucidate the prognostic value of these deletions in more CLL patients, which could be advisable for prognostic and therapeutic purposes, as well as to identify candidate genes that may potentially play a role in the pathogenesis of CLL.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 5. Leukemia, Lymphocytic, Chronic, B-Cell / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620603.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G: Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res; 2009 Jul 1;15(13):4415-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome.
  • PURPOSE: Few biological prognosticators are useful for prediction of Richter syndrome (RS), representing the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma.
  • Stereotyped B-cell receptors (BCR) may have prognostic effect in CLL progression.
  • EXPERIMENTAL DESIGN: The prevalence of stereotyped BCR was compared in RS (n = 69) versus nontransformed CLL (n = 714) by a case-control analysis.
  • Subsequently, the effect of stereotyped BCR at CLL diagnosis on risk of RS transformation was actuarially assessed in a consecutive CLL series (n = 753).
  • RESULTS: RS (n = 69) displayed a higher prevalence of stereotyped BCR (P < 0.001) compared with nontransformed CLL.
  • The actuarial risk of RS transformation was significantly higher in CLL carrying stereotyped BCR (P < 0.001).
  • Among BCR subsets most represented in CLL, subset 8 using IGHV4-39/IGHD6-13/IGHJ5 carried the highest risk of RS transformation [hazard ratio (HR), 24.50; P < 0.001].
  • The combination of IGHV4-39 usage and stereotyped BCR in the same patient identified CLL with a very high risk of RS transformation (5-year risk, 68.7%).
  • The risk carried by stereotyped BCR and IGHV4-39 usage was specific for RS transformation and had no effect on CLL progression without transformation.
  • CONCLUSIONS: Analysis of BCR features may help identify CLL patients at risk of RS.
  • A close monitoring and a careful biopsy policy may help early recognition of RS in CLL patients using stereotyped BCR, particularly if combined with IGHV4-39.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma / genetics. Proto-Oncogene Proteins c-bcr / physiology
  • [MeSH-minor] Aged. Cohort Studies. Disease Progression. Female. Gene Frequency. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Neoplasm Invasiveness. Polymorphism, Genetic / physiology. Risk Factors. Syndrome


38. Bojarska-Junak A, Hus I, Sieklucka M, Wasik-Szczepanek E, Mazurkiewicz T, Polak P, Dmoszynska A, Rolinski J: Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. Oncol Rep; 2010 Sep;24(3):803-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome.
  • The clinical significance of NK-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia (CLL) is still a subject of controversy.
  • There are few previous descriptions that this cell population can be qualitatively or quantitatively deficient in CLL patients.
  • In the present study we investigated the clinical value of CD3+/CD16+ CD56+ cells as predictors of disease progression.
  • We assessed the frequencies of CD3+/CD16+CD56+ cells by the flow cytometry in a group of 300 CLL patients.
  • The percentage of CD3+/CD16+CD56+ cell population expressed as the percentage of CD3+ lymphocyte compartment showed an inverse correlation with ZAP-70 and CD38.
  • The decreased percentage of these cells was associated with higher death risk in CLL patients.
  • Furthermore, the percentage of CD3+/CD16+CD56+ cells was significantly decreased in patients who showed progression of disease.
  • Monitoring of these cell numbers and function may provide useful information for determining disease activity.
  • Especially, it could be intormative to look at these cells in patients with stage 0 CLL.
  • [MeSH-major] Antigens, CD3 / analysis. Antigens, CD56 / analysis. Bone Marrow / immunology. Cytokines / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukocytes, Mononuclear / immunology. Natural Killer T-Cells / immunology. Receptors, IgG / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD38 / analysis. Case-Control Studies. Disease-Free Survival. Female. Flow Cytometry. GPI-Linked Proteins / analysis. Humans. Immunophenotyping / methods. Kaplan-Meier Estimate. Lymphocyte Count. Male. Membrane Glycoproteins / analysis. Middle Aged. Neoplasm Staging. Poland. Time Factors. Treatment Outcome. ZAP-70 Protein-Tyrosine Kinase / analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664990.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD56; 0 / Cytokines; 0 / FCGR3B protein, human; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Receptors, IgG; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


39. Kuramochi K, Matsui R, Matsubara Y, Nakai J, Sunoki T, Arai S, Nagata S, Nagahara Y, Mizushina Y, Ikekita M, Kobayashi S: Apoptosis-inducing effect of epolactaene derivatives on BALL-1 cells. Bioorg Med Chem; 2006 Apr 1;14(7):2151-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epolactaene, a neuritogenic compound in human neuroblastoma SH-SY5Y, induces apoptosis in a human leukemia B-cell line, BALL-1.
  • The alpha-acyl-alpha,beta-epoxy-gamma-lactam moiety as well as the hydrophobicity derived from the long alkyl side chain are both important for activity.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, B-Cell / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Drug Screening Assays, Antitumor. Epoxy Compounds / chemical synthesis. Epoxy Compounds / chemistry. Epoxy Compounds / pharmacology. Humans. Hydrolysis. Molecular Structure. Polyenes / chemical synthesis. Polyenes / chemistry. Polyenes / pharmacology. Stereoisomerism. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298530.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epoxy Compounds; 0 / Polyenes; 0 / epolactaene
  •  go-up   go-down


40. Hubmann R, Düchler M, Schnabl S, Hilgarth M, Demirtas D, Mitteregger D, Hölbl A, Vanura K, Le T, Look T, Schwarzmeier JD, Valent P, Jäger U, Shehata M: NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol; 2010 Mar;148(6):868-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells.
  • One characteristic of chronic lymphocytic leukaemia (CLL) lymphocytes is high expression of CD23, which has previously been identified as a downstream target for NOTCH2 signalling.
  • This study showed that peripheral CLL cells overexpressed transcriptionally active NOTCH2 (N2(IC)), irrespective of their prognostic marker profile.
  • When placed in culture, NOTCH2 activity was spontaneously decreased in 25 out of 31 CLL cases (81%) within 24 h.
  • DNA-bound N2(IC) complexes could be maintained by the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) or by gamma-interferon (IFN-gamma), two CLL characteristic inducers of CD23 expression.
  • Inhibition of PKC-delta by RNA interference or by rottlerin antagonised PMA-induced NOTCH2 activation and also suppressed NOTCH2 activity in CLL cases with constitutively activated NOTCH2 signalling.
  • In 23 out of 29 CLL cases tested (79%), DNA-bound N2(IC) complexes were found to be resistant to the gamma-secretase inhibitor (GSI) DAPT, suggesting that GSIs will be only effective in a subset of CLL cases.
  • These data suggest that deregulation of NOTCH2 signalling is critically involved in maintaining the malignant phenotype of CLL lymphocytes and point to a link between PKC-delta and NOTCH2 signalling in the leukemic cells.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Neoplasm Proteins / metabolism. Protein Kinase C-delta / metabolism. Receptor, Notch2 / metabolism. Receptors, IgE / metabolism

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995395.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / NOTCH2 protein, human; 0 / Neoplasm Proteins; 0 / Receptor, Notch2; 0 / Receptors, IgE; 82115-62-6 / Interferon-gamma; EC 2.7.11.13 / Protein Kinase C-delta; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


41. Gentile M, Lucia E, Iorio C, Vigna E, Mazzone C, Morelli R, Bisconte MG, Gentile C, Morabito F: Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient. Cancer Chemother Pharmacol; 2008 Sep;62(4):741-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
  • INTRODUCTION: Autoimmune hemolytic anemia (AIHA) is a rare and potentially life-threatening event which may complicate the course of chronic lymphocytic leukemia (CLL) at any time and steroid-refractory AIHA of CLL poses a therapeutic challenge for physicians.
  • Here, we report the safety and efficacy of a rituximab-containing regimen in a CLL patient with steroid- and IVIg-refractory AIHA.
  • CASE REPORT: A 57-year- old man affected by CLL, presented with fatigue, dyspnoea, tachycardia and jaundice.
  • The blood chemistry showed severe anemia (Hb value 3.9 g/dL), high white blood cell count (89 x 10(9)/L), altered hemolysis markers and direct antiglobulin test (DAT) was positive for both complement and IgG.
  • CONCLUSION: Our data showed the safety and efficacy of a rituximab-containing regimen in a life-threatening CLL-related AIHA, refractory to steroid and IVIg therapy.
  • This schedule has allowed the patient to obtain a prompt and dramatic rise in hemoglobin level and a response to both AIHA and CLL.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / drug therapy. Antibodies, Monoclonal / therapeutic use. Glucocorticoids / therapeutic use. Immunologic Factors / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Autoimmune Hemolytic Anemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064461.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Glucocorticoids; 0 / Immunoglobulins, Intravenous; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


42. Wołowiec D, Dybko J, Wróbel T, Urbaniak-Kujda D, Jaźwiec B, Tomaszewska-Toporska B, Kapelko-Słowik K, Potoczek S, Kuliczkowski K: Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm; 2006;2006(3):42394
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia.
  • Syndecan-1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of differentiation of B-lymphoid cells.
  • Its prognostic value in B-cell chronic lymphocytic leukemia (B-CLL) has not been evaluated so far.
  • The serum concentration of sCD138 and some angiogenesis-involved cytokines: vascular endothelial growth factor (VEGF), basis fibroblast growth factor (bFGF), and endostatin were studied in 52 previously untreated patients with B-CLL.
  • We found that bFGF and sCD138 levels were significantly higher in B-CLL patients than in controls.
  • In patients with progressive disease bFGF level was significantly higher and sCD138 level significantly lower than in patients with stable one.
  • We conclude that serum sCD138 level is increased in early stage B-CLL patients and may have a positive prognostic value as to the dynamics of the disease.
  • [MeSH-major] Endostatins / blood. Fibroblast Growth Factor 2 / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Membrane Glycoproteins / blood. Proteoglycans / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Syndecan-1. Syndecans

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Aug;106(2):504-9 [10460612.001]
  • [Cites] Annu Rev Cell Biol. 1992;8:365-93 [1335744.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1414-8 [10942237.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2240-5 [10979972.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3181-7 [11050001.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4628-34 [11156212.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1525-9 [11301401.001]
  • [Cites] Br J Haematol. 2001 May;113(2):400-6 [11380405.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):14-7 [11815955.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):31-5 [11857008.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3344-51 [12384436.001]
  • [Cites] Mediators Inflamm. 2003 Jun;12(3):167-71 [12857600.001]
  • [Cites] Cell. 1991 Mar 8;64(5):867-9 [2001586.001]
  • [Cites] Cell Regul. 1989 Nov;1(1):27-35 [2519615.001]
  • [Cites] Adv Cancer Res. 1992;59:115-65 [1381547.001]
  • [Cites] Blood. 1993 Feb 1;81(3):767-74 [8427968.001]
  • [Cites] Leukemia. 1994 Mar;8(3):523-9 [7510358.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3010-6 [7949173.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):2975-82 [7698997.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1978-80 [7772131.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Leukemia. 1997 Feb;11(2):258-65 [9009090.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):368-71 [9375756.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2679-88 [9531576.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):167-75 [9720726.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):412-9 [10050727.001]
  • [Cites] Blood. 2000 Jan 15;95(2):388-92 [10627439.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):761-2 [10942069.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):605-10 [10583266.001]
  • (PMID = 16951490.001).
  • [ISSN] 0962-9351
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endostatins; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC1592593
  •  go-up   go-down


43. Chae HW, Kim IW, Jin HE, Kim DD, Chung SJ, Shim CK: Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch Pharm Res; 2008 Jan;31(1):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to examine the effect of ion-pair complexation with endogenous bile salts on the transport of a quarternary ammonium organic cationic (OC) drug, berberine, across the Caco-2 and LLC-PK1 cell monolayers.
  • Similar results were observed for the transport of berberine across the LLC-PK1 cells.
  • These results suggest that an efflux transporter, probably P-gp, is involved in the Caco-2 cell transport.
  • The apparent partition coefficient (APC) of berberine between n-octanol and a phosphate buffer (pH 7.4) was increased by the presence of an organic anion (OA), taurodeoxycholate (TDC, a bile salt), suggesting the formation of a lipophilic ion-pair complex between an OC (berberine) and an OA (TDC).
  • Despite the ion-pair complexation, however, the BL-AP transport of berberine across the Caco-2 and LLC-PK1 cells was not altered by the cis-presence of bile salts or the rat bile juice.
  • This is consistent with the reportedly unaltered secretory transport of a quarternary ammonium compound, tributylmethylammonium (TBuMA), across the Caco-2 cell monolayers in the cis-presence of bile salts or the rat bile juice, but not with our previous report in which the secretory transport of TBuMA across the LLC-PK1 cell was increased in the cis-presence of TDC.
  • Therefore, the effect of ion-pair formation with the bile components or bile salts on the secretory transport of OCs appears to depend on the molecular properties of OCs (e.g., molecular weight, lipophilicity and affinity to relevant transporters) and the characteristics of cell strains (e.g., expression and contribution of responsible transporters to the transport).
  • [MeSH-minor] Animals. Biological Transport, Active. Caco-2 Cells. Cell Membrane / metabolism. Chemistry, Physical. Chromatography, High Pressure Liquid. Data Interpretation, Statistical. Humans. LLC-PK1 Cells. P-Glycoprotein / antagonists & inhibitors. P-Glycoprotein / metabolism. Physicochemical Phenomena. Solubility. Swine. Taurodeoxycholic Acid / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277615.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / P-Glycoprotein; 0I8Y3P32UF / Berberine; 516-50-7 / Taurodeoxycholic Acid
  •  go-up   go-down


44. Moore DA, Fuller B, Hazzan M, Jones JW: Development of a security vulnerability assessment process for the RAMCAP chemical sector. J Hazard Mater; 2007 Apr 11;142(3):689-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a security vulnerability assessment process for the RAMCAP chemical sector.
  • The Department of Homeland Security (DHS), Directorate of Information Analysis & Infrastructure Protection (IAIP), Protective Services Division (PSD), contracted the American Society of Mechanical Engineers Innovative Technologies Institute, LLC (ASME ITI, LLC) to develop guidance on Risk Analysis and Management for Critical Asset Protection (RAMCAP).
  • AcuTech Consulting Group (AcuTech) has been contracted by ASME ITI, LLC, to provide assistance by facilitating the development of sector-specific guidance on vulnerability analysis and management for critical asset protection for the chemical manufacturing, petroleum refining, and liquefied natural gas (LNG) sectors.
  • This activity involves two key tasks for these three sectors: Development of a screening to supplement DHS understanding of the assets that are important to protect against terrorist attack and to prioritize the activities.
  • Development of a standard security vulnerability analysis (SVA) framework for the analysis of consequences, vulnerabilities, and threats.
  • This project involves the cooperative effort of numerous leading industrial companies, industry trade associations, professional societies, and security and safety consultants representative of those sectors.
  • Jones is the chief technology officer for ASME-ITI, LLC for RAMCAP.

  • MedlinePlus Health Information. consumer health - Disaster Preparation and Recovery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920260.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Hazardous Substances
  •  go-up   go-down


45. Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszynska A: Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol; 2010 Nov;89(11):1115-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
  • Despite many therapeutic regimens introduced recently, chronic lymphocytic leukemia (CLL) is still an incurable disorder.
  • Thus, there is an urgent need to discover novel, less toxic and more effective drugs for CLL patients.
  • In this study, we attempted to assess simvastatin, widely used as a cholesterol-lowering drug, both as a single agent and in combination with purine analogs-fludarabine and cladribine-in terms of its effect on apoptosis and DNA damage of CLL cells.
  • The experiments were done in ex vivo short-term cell cultures of blood and bone marrow cells from newly diagnosed untreated patients.
  • Results of our study revealed that simvastatin induced apoptosis of CLL cells concurrently with lowering of BCL-2/BAX ratio, and its pro-apoptotic effect is tumor-specific, not affecting normal lymphocytes.
  • Interestingly, the rate of apoptosis caused by simvastatin alone and in combination was independent of markers of disease progression like ZAP-70 and CD38 expression or clinical stage according to Rai classification.
  • The results suggest that simvastatin can be used in the treatment of CLL patients as a single agent as well as in combination with purine analogs, being equally effective both in high-risk and good-prognosis patients.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cladribine / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Simvastatin / pharmacology. Tumor Cells, Cultured / drug effects. Vidarabine / analogs & derivatives
  • [MeSH-minor] Anticholesteremic Agents / pharmacology. Antigens, CD38 / metabolism. Apoptosis / drug effects. Ataxia Telangiectasia Mutated Proteins. Caspase 3 / metabolism. Cell Cycle Proteins / metabolism. DNA-Binding Proteins / metabolism. Enzyme Activation. Histones / metabolism. Humans. Prognosis. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Purines / chemistry. Purines / pharmacology. Tumor Suppressor Proteins / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Med. 2000 Apr;32(3):164-76 [10821323.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2712-8 [10946302.001]
  • [Cites] J Investig Med. 2001 Jul;49(4):319-24 [11478407.001]
  • [Cites] Atherosclerosis. 2002 Mar;161(1):17-26 [11882313.001]
  • [Cites] Leukemia. 2002 Apr;16(4):508-19 [11960327.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1436-9 [11986777.001]
  • [Cites] Pharmacotherapy. 2002 Jul;22(7):853-63 [12126219.001]
  • [Cites] Curr Opin Lipidol. 2002 Dec;13(6):637-44 [12441888.001]
  • [Cites] Eur Heart J. 2003 Feb;24(3):225-48 [12590901.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Exp Hematol. 2003 Sep;31(9):779-83 [12962723.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):635-7 [14760377.001]
  • [Cites] Leuk Res. 2004 May;28(5):429-42 [15068894.001]
  • [Cites] Oncol Rep. 2004 May;11(5):1053-8 [15069546.001]
  • [Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III50-7 [15198967.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3628-32 [1673788.001]
  • [Cites] Leuk Lymphoma. 1997 Feb;24(5-6):533-7 [9086443.001]
  • [Cites] Blood. 1997 Jun 1;89(11):4153-60 [9166858.001]
  • [Cites] Blood Rev. 1997 Sep;11(3):119-28 [9370043.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1308-18 [9949174.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):399-408 [10458259.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Transfus Apher Sci. 2005 Feb;32(1):33-44 [15737872.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):883-91 [15705602.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):1113-24 [16142330.001]
  • [Cites] Haematologica. 2006 Apr;91(4):542-5 [16585018.001]
  • [Cites] Methods Mol Biol. 2006;314:81-93 [16673876.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Aug;21(4):364-72 [16999602.001]
  • [Cites] Cell Cycle. 2006 Sep;5(17):1940-5 [16940754.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1389-95 [17089066.001]
  • [Cites] Leukemia. 2007 Feb;21(2):248-52 [17122863.001]
  • [Cites] Cancer Invest. 2007 Aug;25(5):279-84 [17661201.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:444-9 [19074124.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):41-52 [19006566.001]
  • [Cites] Pharmacology. 2009;84(4):191-5 [19729986.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Oct;9(5):365-70 [19858055.001]
  • [Cites] Cancer Res. 2010 Jan 15;70(2):440-6 [20068163.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):10-9 [12538446.001]
  • (PMID = 20499237.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / H2AFX protein, human; 0 / Histones; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Purines; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 47M74X9YT5 / Cladribine; AGG2FN16EV / Simvastatin; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.2.2.5 / Antigens, CD38; EC 3.4.22.- / Caspase 3; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2940031
  •  go-up   go-down


46. Robak E, Jesionek-Kupnicka D, Robak T, Holub A, Wawrzyniak E, Bartkowiak J, Bednarek A, Constantinu M, Urbanska-Rys H: Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia. Br J Dermatol; 2007 Sep;157(3):591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia.
  • Primary cutaneous marginal zone B-cell lymphoma (PCMZL) is a low-grade malignant lymphoma that presents in the skin with no evidence of extracutaneous localization at diagnosis.
  • We present an 80-year-old woman with B-cell chronic lymphocytic leukaemia (CLL) who developed multifocal PCMZL lesions 14 months after CLL diagnosis.
  • PCMZL was clonally similar to the original bone marrow (BM) CLL cells.
  • The specific translocation t(14;18) (q32;q21) with breakpoints in IGH and BCL2 loci was found in a skin specimen, but was absent in BM and peripheral blood (PB) cells.
  • In contrast, a 13q deletion was found in BM and PB CLL cells.
  • To our knowledge this is the first patient with CLL in whom PCMZL has been diagnosed.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697078.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


47. Sureda NC, Bosch MP, Kurpis M, Ruiz Lascano A: [Leukaemia cutis: clinical manifestation of chronic lymphocytic leukaemia relapse]. Rev Fac Cien Med Univ Nac Cordoba; 2007;64(1):42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leukaemia cutis: clinical manifestation of chronic lymphocytic leukaemia relapse].
  • [Transliterated title] Leucemia cutis: expresión clínica de recaída de leucemia linfocítica crónica.
  • We present a 71 year old male patient with previous records of Chronic Lymphocytic Leukaemia who presented with a tumoral skin lesion.
  • Histological and immunohistochemical studies confirmed the Leukaemia Cutis diagnosis.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / pathology. Skin / pathology

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426096.001).
  • [ISSN] 0014-6722
  • [Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)
  • [ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


48. Hock BD, McKenzie JL, McArthur L, Tansley S, Taylor KG, Fernyhough LJ: CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data. Intern Med J; 2010 Dec;40(12):842-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data.
  • AIM: The aim of this study is to determine whether the analysis of CD38 expression by chronic lymphocytic leukaemia (CLL) cells provides useful additional prognostic information.
  • METHODS: Clinical, laboratory, overall survival (OS) and treatment-free survival (TFS) data were collected on 130 CLL patients who had CD38 expression analysed at Canterbury Health Laboratories, New Zealand (NZ) during 1998-2008.
  • RESULTS: The detection of any level of CD38 expression by CLL cells was associated with a significantly shorter OS and TFS.
  • When analysis was restricted to Binet stage A patients, CD38 expression identified a subset of patients (21%) who, in common with Binet stage B/C patients, had a significantly shorter OS and TFS (P<0.0015), and a TFS at 4 years of <10%.
  • In contrast, CD38-negative Binet stage A patients had an OS that was not significantly different from that of an age/sex-matched NZ population and a 5-year TFS of 77%.
  • CONCLUSION: This study indicates that, when combined with clinical staging, the presence of any detectable CD38 expression can be used to further improve the identification of CLL patients with more aggressive disease (i.e.
  • [MeSH-major] Antigens, CD38 / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.
  • (PMID = 20002855.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


49. Omoti CE, Awodu OA, Bazuaye GN: Chronic lymphoid leukaemia: clinico-haematological correlation and outcome in a single institution in Niger Delta region of Nigeria. Int J Lab Hematol; 2007 Dec;29(6):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphoid leukaemia: clinico-haematological correlation and outcome in a single institution in Niger Delta region of Nigeria.
  • Sixty patients were prospectively studied with the aim of analyzing the clinical and laboratory features and outcome of patients diagnosed with chronic lymphocytic leukaemia (CLL) in a major referral center in Niger Delta region of Nigeria for 10 years (1995-2005).
  • The peripheral blood, bone marrow cytology, clinical features and stage at diagnosis were studied.
  • The CLL incidence was 36.4% of total leukaemias.
  • There was a strong association between the blood counts at diagnosis and outcome of therapy.
  • The 2-year survival for young (<55 years) and older (>55 years) CLL patients was 27.2% and 28.9%, respectively, which is still very poor because of a number of strong limiting factors.
  • CLL is not rare in Southern Nigeria and its presentations are similar to cases seen worldwide.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988297.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Kiran S, Cocco P, Mannetje A, Satta G, D'Andrea I, Becker N, de Sanjosé S, Foretova L, Staines A, Kleefeld S, Maynadié M, Nieters A, Brennan P, Boffetta P: Occupational exposure to ethylene oxide and risk of lymphoma. Epidemiology; 2010 Nov;21(6):905-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to ethylene oxide and risk of lymphoma.
  • BACKGROUND: Ethylene oxide, a high-volume commodity, is an established human carcinogen, although the relevant epidemiologic evidence is limited.
  • METHODS: We explored the association between occupational exposure to ethylene oxide and risk of lymphoma in a case-control study, including 2347 lymphoma cases first diagnosed in 1998-2004 and 2463 controls, from 6 European countries.
  • The diagnosis of lymphoma was based on the 2001 World Health Organization Classification of lymphoma.
  • We modeled risk of lymphoma with unconditional logistic regression analysis as a function of various exposure measures, adjusting for age, sex, and participating center.
  • Lymphoma risk showed a 4.3-fold increase associated with medium-high frequency of exposure to ethylene oxide (95% CI = 1.4-13).
  • Among major subtypes, chronic lymphocytic leukemia was consistently associated with ethylene oxide exposure, related in a dose-response manner to probability, frequency, and duration of exposure, as well as to cumulative exposure and (less definitively) with exposure intensity.
  • [MeSH-major] Carcinogens / toxicity. Ethylene Oxide / toxicity. Lymphoma / chemically induced. Occupational Exposure

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYLENE OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811284.001).
  • [ISSN] 1531-5487
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; JJH7GNN18P / Ethylene Oxide
  •  go-up   go-down


51. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J: The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol; 2010 Jan 1;84(1):1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MicroRNAs are small non-coding RNAs that act at the post-transcriptional level, regulating protein expression by repressing translation or destabilizing mRNA target.
  • Because of their discovery, microRNAs have been associated with almost every normal cell function, including proliferation, differentiation and apoptosis.
  • Several lines of evidence suggest that they have an important role in normal hematopoiesis as exemplified by the role of mir-155 and mir-150 in the differentiation of B and T lymphocytes, the suppressive role of mir-221 and mir-222 in erythroid differentiation, the inhibitory effect of mir-181 on hematopoietic differentiation and the induction of myeloid differentiation by mir-223.
  • Their aberrant expression has been associated with solid tumors and hematopoietic malignancies as suggested by the frequent deletion of mir-15a and mir-16-1 in chronic lymphocytic leukemia, the increased levels of mir-155 in diffuse large B-cell lymphomas and the increased levels of mir-181 in acute myeloid leukemia M1 and M2.
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / genetics. Down-Regulation. Erythroid Precursor Cells / cytology. Gene Expression Regulation, Neoplastic / genetics. Genes, Tumor Suppressor. Humans. Invertebrates / genetics. Lymphocytes / cytology. Mice. Myeloid Cells / cytology. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Oncogenes. RNA, Neoplasm / antagonists & inhibitors. RNA, Neoplasm / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744129.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  • [Number-of-references] 110
  •  go-up   go-down


52. Guastafierro S, Celentano M, Cuomo C, Falcone U: Chronic lymphocytic leukemia with associated lambda-light-chain and IgG lambda paraproteins simulating a biclonal gammopathy. Clin Lab; 2010;56(11-12):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia with associated lambda-light-chain and IgG lambda paraproteins simulating a biclonal gammopathy.
  • BACKGROUND: Monoclonal components (MCs) are frequently detected in the sera of patients with B-cell malignancies, by techniques that are getting more and more sensitive.
  • Only few chronic lymphocytic leukemia (CLL) patients with multiple serum paraproteins are reported in the literature.
  • METHODS: In this case report we present a 71-year-old woman with CLL and serum MCs.
  • The bone marrow aspiration and biopsy revealed a 38 % interstitial and nodular infiltration of mature small lymphocytes expressing IgG lambda surface immunoglobulins CD 19, CD20, CD5, and CD23, with negative BCL-1, t(11, 14) and cyclin D1.
  • Final diagnosis was CLL (Rai stage I) with IgG lamda plus lamda serum paraproteins.
  • Three years later, the patient died because of myocardial infarction after a follow-up period with no need for CLL therapy.
  • CONCLUSIONS: Our hypothesis is that the double MC may be the result of an unbalanced immunoglobulin chain synthesis by the leukemic B-cell clone, resulting in IgGlamda and excess of lambda FLCs.
  • [MeSH-major] Immunoglobulin G / blood. Immunoglobulin lambda-Chains / blood. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Paraproteinemias / blood. Paraproteins / analysis


53. Woyach JA, Heerema NA, Zhao J, McFaddin A, Stark A, Lin TS, Andritsos LA, Blum KA, Flynn JM, Jones JA, Byrd JC: Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. Br J Haematol; 2010 Mar;148(5):754-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.
  • Interphase cytogenetics are commonly used to identify clonal abnormalities in chronic lymphocytic leukemia (CLL) patients but fail to identify recurrent translocations that ultimately can direct more focused molecular characterization.
  • Given the importance of del(17p13.1) in CLL outcome, we performed an extensive review of 1213 patients undergoing metaphase cytogenetics at our institution and identified 16 (1.3%) with a recurrent unbalanced translocation between the p arms of chromosomes 17 and 18 that results in a dicentric chromosome with loss of much of 17p and 18p.
  • The dic(17;18)(p11.2;p11.2) was associated with a complex (three or more unrelated cytogenetic abnormalities) karyotype in 12 patients (75%) at the time that the abnormality was first identified, and eventually associated with a complex karyotype in 94% of patients.
  • Except for one patient who was diagnosed with CLL incidentally during a workup for metastatic tonsillar cancer, all patients identified with dic(17;18)(p11.2;p11.2) met criteria for disease treatment, with a median time from diagnosis to first treatment of 15 months.
  • Our data demonstrate that dic(17;18)(p11.2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression.
  • Future efforts to identify genes disrupted by this translocation are warranted and ongoing.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jul 1;96(1):377-9 [10939807.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1715-22 [17541398.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Eur J Haematol. 2002 Nov-Dec;69(5-6):309-14 [12460236.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1101-16 [12649807.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):417-20 [12800154.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):720-4 [2201915.001]
  • [Cites] Leukemia. 1992 Apr;6(4):246-50 [1588788.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3148-57 [7949187.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4342-9 [9596683.001]
  • [Cites] Leukemia. 1999 Mar;13(3):460-8 [10086737.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:163-83 [15561682.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):437-43 [16344317.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jun;167(2):177-81 [16737921.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 15;168(2):109-19 [16843100.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Mar;173(2):136-43 [17321329.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Sep;121(2):194-7 [11063807.001]
  • (PMID = 20015097.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA102276-05; United States / NCI NIH HHS / CA / CA102276-05; United States / NCI NIH HHS / CA / CA016058-309023; United States / NCI NIH HHS / CA / P30 CA 16058; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / P30 CA016058-309023; United States / NCI NIH HHS / CA / K23 CA102276
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS213244; NLM/ PMC2902554
  •  go-up   go-down


54. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP: Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology; 2006 Jul;118(3):281-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.
  • B-cell chronic lymphocytic leukaemia (B-CLL) is the most prevalent leukaemia in Western countries and is characterized by the gradual accumulation in patients of small mature B cells.
  • Although the phenomenon is relevant in vivo, B-CLL cells die rapidly in vitro as a consequence of apoptosis, suggesting a lack of essential growth factors in the culture medium.
  • Indeed, the rate of B-CLL cell death in vitro is modulated by different cytokines, some favouring the apoptotic process, others counteracting it.
  • Two related members of the tumour necrosis factor family, BAFF (B-cell activating factor of the TNF family) and APRIL (a proliferation-inducing ligand), already known for their crucial role in normal B-cell survival, differentiation and apoptosis, were recently shown to be expressed by B-CLL cells.
  • It will discuss the expression of these molecules by B-CLL cells, their regulation, transduction pathways and their effects on leukaemic cells.
  • The design of reagents able to counteract the effects of these molecules seems to be a new promising therapeutic approach for B-CLL and is already currently developed in the treatment of autoimmune diseases.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / blood. Membrane Proteins / physiology. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] B-Cell Activating Factor. Biomarkers, Tumor / blood. Cell Survival. Humans. Neoplasm Proteins / blood. Neoplasm Proteins / physiology. Tumor Necrosis Factor Ligand Superfamily Member 13

  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Aug 1;92(3):1031-43 [9680373.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4464-71 [12531790.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):311-24 [12787568.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):547-51 [12847217.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33127-33 [12796483.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38220-8 [12867412.001]
  • [Cites] Arthritis Rheum. 2003 Nov;48(11):3253-65 [14613291.001]
  • [Cites] Curr Drug Targets Cardiovasc Haematol Disord. 2003 Dec;3(4):261-86 [14683470.001]
  • [Cites] Blood. 2004 Jan 15;103(2):679-88 [14504101.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):762-6 [14707045.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):251-5 [15023421.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):107-14 [10561025.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1021-7 [10706119.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3370-5 [10716715.001]
  • [Cites] Nature. 2000 Apr 27;404(6781):995-9 [10801128.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):137-43 [10880535.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1322-30 [10903733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9156-61 [10908663.001]
  • [Cites] Science. 2000 Aug 11;289(5481):883-4 [10960320.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1685-94 [10995017.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1185-90 [9743536.001]
  • [Cites] J Leukoc Biol. 1999 May;65(5):680-3 [10331498.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):15978-81 [10347144.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]
  • [Cites] Science. 1999 Jul 9;285(5425):260-3 [10398604.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1934-40 [15483672.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:163-83 [15561682.001]
  • [Cites] Curr Dir Autoimmun. 2005;8:266-88 [15564725.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7394-400 [15585864.001]
  • [Cites] J Mol Recognit. 2005 Jan-Feb;18(1):94-102 [15382264.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):35-9 [15630136.001]
  • [Cites] Biochemistry. 2005 Feb 15;44(6):1919-31 [15697217.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10018-24 [15644327.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1375-83 [15851487.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):637-48 [15846369.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):319-28 [15972664.001]
  • [Cites] Virchows Arch. 2005 Jul;447(1):53-60 [16025281.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1021-30 [15827134.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1012-20 [15860672.001]
  • [Cites] Immunol Lett. 2005 Oct 15;101(1):87-94 [15939481.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1113-9 [16226112.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):1547-52 [11591325.001]
  • [Cites] J Immunol. 2003 May 1;170(9):4593-600 [12707337.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):953-64 [11015437.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35478-85 [10956646.001]
  • [Cites] J Exp Med. 2000 Nov 20;192(10):1453-66 [11085747.001]
  • [Cites] Blood. 2001 Jan 1;97(1):198-204 [11133761.001]
  • [Cites] Cytokine. 2001 Jan 7;13(1):25-31 [11145839.001]
  • [Cites] Nat Immunol. 2000 Sep;1(3):252-6 [10973284.001]
  • [Cites] Nat Immunol. 2000 Jul;1(1):37-41 [10881172.001]
  • [Cites] Immunity. 2001 May;14(5):573-82 [11371359.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):577-8 [11429537.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):638-43 [11429549.001]
  • [Cites] Rev Clin Exp Hematol. 2000 Mar;4(1):5-21 [11491097.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2111-4 [11509691.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]
  • [Cites] EMBO Rep. 2001 Oct;2(10):945-51 [11571266.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6225-31 [11714784.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1691-7 [11733583.001]
  • [Cites] Curr Biol. 2001 Dec 11;11(24):1986-9 [11747827.001]
  • [Cites] Exp Hematol. 2002 Feb;30(2):135-41 [11823048.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):266-75 [11869903.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):5993-6 [12055205.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1587-98 [12070306.001]
  • [Cites] J Leukoc Biol. 2002 Aug;72(2):410-6 [12149433.001]
  • [Cites] Nat Immunol. 2002 Sep;3(9):822-9 [12154359.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • [Cites] Immunity. 2002 Sep;17(3):235-8 [12354377.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4314-21 [12370363.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:193-213 [12446424.001]
  • [Cites] J Biol Regul Homeost Agents. 2002 Jul-Sep;16(3):211-3 [12456020.001]
  • [Cites] J Immunol. 2002 Dec 15;169(12):6883-9 [12471121.001]
  • [Cites] Blood. 2003 Jan 1;101(1):278-85 [12393642.001]
  • [Cites] Annu Rev Immunol. 2003;21:231-64 [12427767.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):347-54 [15251127.001]
  • [Cites] J Mol Biol. 2004 Oct 15;343(2):283-90 [15451660.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]
  • [Cites] Immunity. 2004 Oct;21(4):477-89 [15485626.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):399-408 [15488762.001]
  • [Cites] EMBO J. 1992 Nov;11(11):3897-904 [1396583.001]
  • [Cites] Nucleic Acids Res. 1994 Apr 11;22(7):1147-54 [8165126.001]
  • [Cites] Science. 1997 Oct 3;278(5335):138-41 [9311921.001]
  • (PMID = 16827889.001).
  • [ISSN] 0019-2805
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / TNFSF13 protein, human; 0 / TNFSF13B protein, human; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13; 0 / Tumor Necrosis Factor-alpha
  • [Number-of-references] 86
  • [Other-IDs] NLM/ PMC1782305
  •  go-up   go-down


55. Heinzelmann F, Ottinger H, Müller CH, Allgaier S, Faul C, Bamberg M, Belka C: Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST). Strahlenther Onkol; 2006 Apr;182(4):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total-body irradiation--role and indications: results from the German Registry for Stem Cell Transplantation (DRST).
  • BACKGROUND AND PURPOSE: Total-body irradiation (TBI) is a key part of the conditioning regimen before hematopoietic stem cell transplantation (HSCT).
  • In order to determine the relevance of TBI, the status of TBI utilization was analyzed on the basis of a nationwide registry.
  • MATERIAL AND METHODS: 14,371 patients (1998-2002) documented in the German Stem Cell Transplantation Registry (DRST) were analyzed regarding TBI utilization prior to autologous or allogeneic transplantation, underlying disorder, type of donor, stem cell source, and size of the treatment center.
  • RESULTS: For autologous HSCT approximately 10% of the patients (873/8,167) received TBI, with chronic lymphocytic leukemia (CLL, approximately 80%, 171/214) and low-grade non-Hodgkin's lymphoma (l-NHL, approximately 35%, 330/929) being the most important disorders.
  • In the allogeneic setting 50% of the patients (2,399/4,904) received TBI, with acute lymphocytic leukemia (ALL, 85%, 794/930), acute myeloid leukemia (AML, 45%, 662/1,487) and chronic myeloid leukemia (CML, 49%, 561/1,156) being the key indications.
  • The type of donor, stem cell source and center size did not strongly influence the use of TBI.
  • CONCLUSION: TBI has only a limited role for the conditioning prior to autologous HCST.
  • [MeSH-major] Registries. Stem Cell Transplantation. Transplantation Conditioning. Whole-Body Irradiation
  • [MeSH-minor] Acute Disease. Germany. Histocompatibility Testing. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy. Lymphoma, Non-Hodgkin / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622624.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


56. Li HX, Yan FH, Lei L: [Effects of Porphyromonas gingivalis lipopolysaccharide on apoptotic genes in foam cells]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 May;45(5):274-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Macrophages from THP-1 monocytes and foam cells from macrophages by oxLDL inducement were treated with oxidized low density lipoprotein (oxLDL) or oxLDL+ Pg-LPS.
  • Cell apoptosis was detected by acridine orange-ethidium bromide (AO-EB) staining.
  • RESULTS: Pg-LPS enhanced cell apoptosis rate during and after foam cells formation [(5.47+/-0.93)% vs. (7.50+/-0.54)%].
  • PCR array demonstrated that it increased B-cell CLL-lymphoma 2 (BCL2) related protein A1 (BCL2A1) transcription during foam cells formation (>2 fold), and promoted BCL2 and BCL2A1 transcription after foam cells formation (>2 fold).
  • CONCLUSIONS: Pg-LPS affected apoptotic gene transcription during and after foam cells formation and enhanced cell apoptosis.
  • [MeSH-minor] Caspase 3 / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Gene Expression. Humans. Lipoproteins, LDL / pharmacology. Macrophages / physiology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654241.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL2-related protein A1; 0 / Lipopolysaccharides; 0 / Lipoproteins, LDL; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; 0 / oxidized low density lipoprotein; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


57. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N: Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma; 2010 Dec;51(12):2222-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.
  • Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL.
  • Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):593-7 [17928052.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Leuk Lymphoma. 2009 Jan;50(1):62-7 [19125384.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Br J Haematol. 2009 Sep;146(6):660-4 [19604237.001]
  • [Cites] Blood. 2010 Jan 28;115(4):846-9 [19965686.001]
  • [Cites] Blood. 2010 Jun 3;115(22):4447-54 [20164467.001]
  • [Cites] Leuk Lymphoma. 2010 Jul;51(7):1351-3 [20496991.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):353-6 [20182346.001]
  • [Cites] Clin Cancer Res. 2010 Jul 1;16(13):3390-8 [20570929.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):605-10 [10583266.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Leukemia. 2000 Aug;14(8):1414-8 [10942237.001]
  • [Cites] Leuk Res. 2001 Apr;25(4):279-85 [11248324.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):795-9 [11309324.001]
  • [Cites] Leukemia. 2002 May;16(5):911-9 [11986954.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3344-51 [12384436.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Leuk Res. 2004 Mar;28(3):243-8 [14687619.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Blood. 2004 Aug 1;104(3):788-94 [14996703.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):965-70 [10070898.001]
  • [Cites] Leukemia. 2005 Apr;19(4):513-23 [15703780.001]
  • [Cites] Leukemia. 2005 Apr;19(4):524-30 [15674425.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4813-9 [15731179.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Leukemia. 2006 Apr;20(4):583-9 [16467866.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):174-85 [16616064.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Leukemia. 2007 Jan;21(1):44-52 [16990761.001]
  • [Cites] Vnitr Lek. 2007 Nov;53(11):1171-6 [18277626.001]
  • (PMID = 21054149.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CM62205; United States / NCI NIH HHS / CM / N01-CM62207; United States / NCI NIH HHS / CM / N01 CM062205; United States / NCI NIH HHS / CA / U24 CA114740; United States / NCI NIH HHS / CA / CA113408; United States / NCI NIH HHS / CM / N01-CM62205; United States / NCI NIH HHS / CA / CA114740; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / N01CM62207; United States / NCI NIH HHS / CA / CA116237; United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CM / N01 CM062207; United States / NCI NIH HHS / CA / R01 CA116237; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / Quinazolines; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; NQU9IPY4K9 / cediranib; V99T50803M / sunitinib
  • [Other-IDs] NLM/ NIHMS550827; NLM/ PMC3928074
  •  go-up   go-down


58. Burton BJ, Cunningham ET Jr, Cree IA, Pavesio CE: Eye involvement mimicking scleritis in a patient with chronic lymphocytic leukaemia. Br J Ophthalmol; 2005 Jun;89(6):775-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eye involvement mimicking scleritis in a patient with chronic lymphocytic leukaemia.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / diagnosis. Sclera / pathology. Scleritis / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eye (Lond). 2003 Jan;17(1):27-30 [12579166.001]
  • [Cites] Arch Ophthalmol. 1961 Oct;66:490-508 [13860566.001]
  • [Cites] Surv Ophthalmol. 1983 Jan-Feb;27(4):211-32 [6342189.001]
  • [Cites] Br J Ophthalmol. 1968 Oct;52(10):781-5 [5686969.001]
  • (PMID = 15923522.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772664
  •  go-up   go-down


59. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M: Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol; 2009 Feb;88(2):121-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.
  • Infection is a significant cause of morbidity and death in patients with chronic lymphocytic leukemia (CLL).
  • Increased infectious events may arise from the multiple courses of immunosuppressive therapy and progressive deterioration of a patient's immune system over the course of disease.
  • The humanized, anti-CD52 monoclonal antibody alemtuzumab (Campath or Campath-1H) has shown notable activity for both untreated and fludarabine-refractory CLL.
  • The cumulative effects of the malignancy and successive courses of treatments adversely impinge on a patient's defense response to certain bacterial, fungal, and viral infections.
  • In this review article, we provide an overview of common infectious events associated with alemtuzumab therapy in CLL.
  • We also discuss recommendations for effectively monitoring and managing infections in CLL patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Infection / complications. Infection / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682948.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Number-of-references] 64
  •  go-up   go-down


60. Gao Y, Kristinsson SY, Goldin LR, Björkholm M, Caporaso NE, Landgren O: Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology; 2009 Jan;136(1):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association.
  • BACKGROUND & AIMS: Celiac disease (CD), a common digestive disease, is well known to be associated with excess non-Hodgkin lymphoma (NHL) risk.
  • However, there are only limited data on risk in the current era of serologic testing and human leukocytes antigen typing to screen for CD.
  • There is also no information on the role of family history of CD in relation to lymphoma risk.
  • METHODS: We identified 37,869 NHL, 8323 Hodgkin lymphoma (HL), and 13,842 chronic lymphocytic leukemia patients diagnosed in Sweden between 1965 and 2004, as well as 236,408 matched controls and 613,961 first-degree relatives.
  • RESULTS: Overall we found persons with a hospital discharge diagnosis of CD to have a 5.35-fold (95% CI, 3.56-8.06) increased NHL risk.
  • Risk of HL was borderline increased (OR=2.54, 95% CI, 0.99-6.56); however, there was no excess chronic lymphocytic leukemia risk.
  • Persons diagnosed with CD in 1975-1984, 1985-1994, and 1995-2004 had a 13.2-fold (95% CI, 3.63-48.0), 7.90-fold (95% CI, 3.38-18.5), and 3.84-fold (95% CI, 2.28-6.45) increased risk of NHL, respectively (P(trend)< .0001).
  • Future studies are needed to explore the roles of gluten intake, secondary intestinal inflammation, and susceptibility genes in relation to subsequent risk of developing lymphoma.
  • [MeSH-major] Celiac Disease / complications. Celiac Disease / genetics. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Male. Middle Aged. Risk


61. Crespo M, Villamor N, Giné E, Muntañola A, Colomer D, Marafioti T, Jones M, Camós M, Campo E, Montserrat E, Bosch F: ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
  • PURPOSE: The ZAP-70 gene is normally expressed in T and natural killer cells, where it is required for the T-cell receptor (TCR) signaling.
  • More recently, it has been described that ZAP-70 contributes to the B-cell development at early stages of B-cell differentiation in mice.
  • The purpose was to investigate the presence of ZAP-70 in normal pro/pre B cells and mature B cells and in tumoral cells from B-acute lymphoblastic leukemias (B-ALL).
  • Among tumoral cells, ZAP-70 was expressed in 56% of B-ALLs with pro/pre B-cell phenotype and in 4 of 6 Burkitt/ALL lymphomas.
  • CONCLUSIONS: Among normal B-cell subsets, ZAP-70 was found expressed in normal pro/pre B cells but not in a significant proportion of normal B cells with mature phenotype.
  • The lack of ZAP-70 expression in normal mature B cells suggests that its expression in mature-derived neoplasms with different cellular origin, such as Burkitt's lymphoma and chronic lymphocytic leukemia, might be due to an aberrant phenomenon.
  • [MeSH-major] B-Lymphocytes / metabolism. Burkitt Lymphoma / genetics. Gene Expression Regulation. Gene Expression Regulation, Leukemic. Hematopoietic Stem Cells / metabolism. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Mutational Analysis. Humans. Middle Aged. Phenotype. Phosphorylation. Receptors, Antigen, T-Cell / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467082.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


62. Klabusay M, Sukova V, Coupek P, Brychtova Y, Mayer J: Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry B Clin Cytom; 2007 Sep;72(5):363-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
  • The authors analyzed the intensity of the CD52 antigen expression in patients with chronic lymphoproliferative diseases and compared them with B-lymphocytes of a healthy population and CD34(+) cells in peripheral blood stem cells (PBSC) grafts.
  • METHODS: Recently diagnosed and previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL), mantle-cell lymphoma (MCL), or small lymphocytic lymphoma (SLL) were evaluated and compared with control group and CD34(+) cells.
  • RESULTS: In the group of patients with B-CLL, the CD52 level on tumor cells (245 x 10(3) MESF; 107 x 10(3) ABC) was significantly lower than on B-lymphocytes of the control group (446 x 10(3) MESF; 194 x 10(3) ABC; P < 0.001) and SLL tumor cells (526 x 10(3) MESF; 229 x 10(3) ABC; P < 0.001).
  • The CD52 antigen was expressed on a majority of CD34(+) cells, but its expression intensity was low (101 x 10(3) MESF; 44 x 10(3) ABC).
  • CONCLUSIONS: Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells.
  • CD52 antigen is expressed at low level on CD34(+) cells.
  • [MeSH-major] Antigens, CD / analysis. Antigens, CD34 / biosynthesis. Antigens, Neoplasm / analysis. B-Lymphocytes / immunology. Flow Cytometry / methods. Glycoproteins / analysis. Hematopoietic Stem Cells / immunology. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers / analysis. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Chronic Disease. Female. Humans. Leukemia, B-Cell / blood. Leukemia, B-Cell / diagnosis. Leukemia, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphocyte Activation / immunology. Lymphoma, Mantle-Cell / blood. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / immunology. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Clinical Cytometry Society.
  • (PMID = 17428002.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


63. Caldas LA, Attias M, de Souza W: Dynamin inhibitor impairs Toxoplasma gondii invasion. FEMS Microbiol Lett; 2009 Nov;301(1):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that previous incubation of the host cells, but not the parasites, with Dynasore, a small molecule that inhibits dynamin GTPase activity, markedly reduced the penetration of T. gondii tachyzoites into LLC-MK2 cells.
  • In contrast, parasite adhesion to the host cell surface increased, as observed both by light and electron microscopy.
  • Intriguingly, the few parasites internalized by Dynasore-treated cells remained in vacuoles located at the periphery of the cell, in contrast to the perinuclear localization seen in the control.
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line. Dose-Response Relationship, Drug. Host-Parasite Interactions. Humans. Hydrazones / administration & dosage. Macaca mulatta. Mice. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Vacuoles / metabolism. Vacuoles / parasitology

  • MedlinePlus Health Information. consumer health - Toxoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817867.001).
  • [ISSN] 1574-6968
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazones; 0 / N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide; EC 3.6.5.5 / Dynamins
  •  go-up   go-down


64. Giannopoulos K, Li L, Bojarska-Junak A, Rolinski J, Dmoszynska A, Hus I, Greiner J, Renner C, Döhner H, Schmitt M: Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol; 2006 Jul;29(1):95-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
  • Antigen targeted immunotherapies might represent a novel treatment for B-cell chronic lymphocytic leukemia (B-CLL).
  • Peripheral blood mononuclear cells from 43 B-CLL patients and 20 healthy volunteers (HVs) were examined by conventional and quantitative RT-PCR. mRNA of RHAMM/CD168, fibromodulin, syntaxin and NY-Ren60 was expressed in 55-90%, and mRNA of HSJ2, MAZ and OFAiLRP was expressed in 90-100% of the patients.
  • Low (2-20%) expression frequencies of MPP11, PINCH, PRAME and proteinase were detected.
  • RHAMM/CD168, fibromodulin, PRAME and MPP11 showed expression in B-CLL patients, but not in Hvs. Because of the exquisite tissue expression of RHAMM/CD168 and its high expression frequency in CLL patients, mixed lymphocyte peptide culture (MLPC), enzyme-linked immunosorbent spot (ELISPOT) and flow cytometry were performed for antigen specific T-cells.
  • RHAMM/CD168 might be a possible target for future immunotherapies in both ZAP-70(+) and ZAP-70(-) B-CLL patients.
  • [MeSH-major] Antigens, CD44 / immunology. Extracellular Matrix Proteins / immunology. Gene Expression Regulation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukocytes, Mononuclear / immunology
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / biosynthesis. Antigens, Neoplasm / genetics. Cells, Cultured. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Male. Middle Aged. Oligopeptides / immunology. Oncogene Proteins / biosynthesis. Oncogene Proteins / genetics. Proteoglycans / biosynthesis. Proteoglycans / genetics. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773189.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / DNAJC2 protein, human; 0 / Extracellular Matrix Proteins; 0 / Oligopeptides; 0 / Oncogene Proteins; 0 / PRAME protein, human; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / hyaluronan-mediated motility receptor; 126468-95-9 / fibromodulin; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


65. Cabrelle A, Maschio N, Carraro S, Frezzato F, Binotto G, Gattazzo C, Miorin M, Agostini C, Zambello R, Pandolfi F, Semenzato G, Trentin L: Apoptotic effect of cyclosporin a and dexamethasone in malignant cells of patients with B-chronic lymphocytic leukemia. J Biol Regul Homeost Agents; 2009 Oct-Dec;23(4):239-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic effect of cyclosporin a and dexamethasone in malignant cells of patients with B-chronic lymphocytic leukemia.
  • B-chronic lymphocytic leukemia (B-CLL) is a malignant disorder characterized by the accumulation of the leukemic cells in the G0-G1 phase of the cell cycle and expressing high levels of the anti-apoptotic protein Bcl-2.
  • Since we observed that the treatment of autoimmune complications with Cyclosporine A (CsA) determined in some CLL patients an improvement not only of the autoimmune phenomena, but also of the leukemic process, we evaluated the in vitro cytotoxicity of CsA as compared to Dexamethasone (Dex) on leukemic cells.
  • Leukemic cells obtained from 32 B-CLL patients showed a heterogeneous pattern of spontaneous apoptosis at 24 h interval and this pattern permitted to identify: Group 1 (14/32) with high (>20%) apoptotic rate and Group 2 (18/32) with low cell death.
  • CsA and Dex increased cell death in both groups with a different timing by an apoptotic mechanism that does not involve Bcl-2.
  • We suggest that, in B-CLL, CsA has a significant pro-apoptotic activity manifested also in patients with low spontaneous apoptosis.
  • Our observations might be taken into account to consider new therapeutic strategies in B-CLL.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Apoptosis / drug effects. Cyclosporine / pharmacology. Dexamethasone / pharmacology. Immunosuppressive Agents / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20003763.001).
  • [ISSN] 0393-974X
  • [Journal-full-title] Journal of biological regulators and homeostatic agents
  • [ISO-abbreviation] J. Biol. Regul. Homeost. Agents
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 7S5I7G3JQL / Dexamethasone; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


66. Nückel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, Jöckel KH, Dührsen U, Siffert W: Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood; 2007 Jan 1;109(1):290-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.
  • We investigated the role of a novel regulatory single-nucleotide polymorphism (-938C>A) in the inhibitory P2 BCL2 promoter in B-cell chronic lymphocytic leukemia (B-CLL).
  • Concomitantly, Bcl-2 protein expression in B cells from CLL patients carrying the -938 AA genotype was significantly increased compared with CC genotypes.
  • Genotype distribution between 123 CLL patients (42 AA, 55 AC, 26 CC) and 120 genotyped healthy controls (36 AA, 63 AC, 21 CC) was not significantly different, suggesting that genotypes of this polymorphism do not increase the susceptibility for B-CLL.
  • However, median time from first diagnosis to initiation of chemotherapy and median overall survival were significantly shorter in patients with -938AA genotype (38 and 199 months, respectively) compared with AC/CC genotypes (120 and 321 months, respectively; P = .008 and P = .003, respectively).
  • Multivariable Cox regression identified the BCL2-938AA genotype as an independent prognostic factor for the time to first treatment (hazard ratio [HR] 1.9; P = .034) together with disease stage at diagnosis (HR 2.5; P = .004) and ZAP-70 status (HR 3.0; P = .001).
  • The BCL2-938AA genotype is associated with increased Bcl-2 expression and a novel unfavorable genetic marker in patients with B-CLL.
  • [MeSH-major] Biomarkers, Tumor / genetics. Genes, bcl-2. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Aged. Alleles. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line. Chromosome Aberrations. Chromosomes, Human / genetics. Chromosomes, Human / ultrastructure. Disease Progression. Female. Genotype. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Transcription, Genetic. Transfection. ZAP-70 Protein-Tyrosine Kinase / analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Jan 1;111(1):466-8 [18156504.001]
  • (PMID = 16960146.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


67. Guggisberg K, Jordan RC: Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan;109(1):98-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature.
  • OBJECTIVE: Mantle cell lymphoma (MCL) is a rare B-cell neoplasm that has only recently been defined as a distinct entity.
  • Because of its rarity and histologic similarities to other small cell lymphomas, the microscopic diagnosis of MCL may be challenging.
  • This is particularly true within the oral cavity, where other lymphomas are more frequent.
  • Historical cases were reviewed, and available data regarding morphology, special stains, demographics, clinical presentation, radiographic findings, management, and outcome were extracted.
  • CONCLUSION: We conclude that MCL of the oral cavity is an uncommon diagnosis.
  • The microscopic diagnosis can be challenging, given its similar appearance to other small cell lymphomas, requiring a comprehensive immunohistochemical panel for the accurate diagnosis.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):186-92 [15191005.001]
  • [Cites] J Oral Pathol. 1987 Jan;16(1):8-12 [3104566.001]
  • [Cites] Blood. 1990 Oct 1;76(7):1387-91 [2207314.001]
  • [Cites] Blood. 1991 Jul 15;78(2):259-63 [2070063.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):802-111 [8478674.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):249-56 [7612490.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):257-62 [7612491.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):627-40 [8619427.001]
  • [Cites] Curr Top Pathol. 1996;90:125-46 [8791750.001]
  • [Cites] Ear Nose Throat J. 1997 Jan;76(1):35-6 [9018933.001]
  • [Cites] J Oral Pathol Med. 1997 Jul;26(6):283-9 [9234189.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] Ann Hematol. 2004 Feb;83(2):71-7 [14669040.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):316-20 [12973287.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Nov;92(5):519-25 [11709688.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):391-5 [16053848.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] J Laryngol Otol. 1998 Oct;112(10):991-4 [10211231.001]
  • [Cites] Head Neck. 1999 May;21(3):247-54 [10208668.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):637-40 [1530105.001]
  • [Cites] Cancer. 2008 Aug 15;113(4):791-8 [18615506.001]
  • [Cites] Blood. 2008 Jan 15;111(2):558-65 [17962512.001]
  • [Cites] Histopathology. 2006 Mar;48(4):353-62 [16487357.001]
  • [Cites] Tumori. 2005 Nov-Dec;91(6):456-62 [16457141.001]
  • (PMID = 19880332.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / T32 DE017249; United States / NIDCR NIH HHS / DE / T32 DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE017249-05; United States / NIDCR NIH HHS / DE / DE017249-04; United States / NIDCR NIH HHS / DE / T32 DE019096-02; United States / NIDCR NIH HHS / DE / DE017249-01; United States / NCI NIH HHS / CA / R21 CA095231; United States / NIDCR NIH HHS / DE / DE019096-02; United States / NIDCR NIH HHS / DE / T32 DE017249-03; United States / NCI NIH HHS / CA / R33 CA095231; United States / NIDCR NIH HHS / DE / T32 DE019096; United States / NIDCR NIH HHS / DE / T32DE017249; United States / NIDCR NIH HHS / DE / DE019096-01; United States / NIDCR NIH HHS / DE / T32 DE017249-02; United States / NIDCR NIH HHS / DE / DE017249-02; United States / NIDCR NIH HHS / DE / T32 DE019096-01; United States / NIDCR NIH HHS / DE / DE017249-03; United States / NIDCR NIH HHS / DE / T32 DE017249-01; United States / NIDCR NIH HHS / DE / DE017249-05; United States / NIDCR NIH HHS / DE / T32DE019096; United States / NCI NIH HHS / CA / CA095231
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  • [Number-of-references] 29
  • [Other-IDs] NLM/ NIHMS156688; NLM/ PMC2818374
  •  go-up   go-down


68. Wei J, Zhou S, Bachem MG, Debatin KM, Beltinger C: Infiltration of blood outgrowth endothelial cells into tumor spheroids: role of matrix metalloproteinases and irradiation. Anticancer Res; 2007 May-Jun;27(3B):1415-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Infiltration of BOECs into spheroids made of tumor cells and fibroblasts was determined in the presence of low-dose EDTA, a potent inhibitor of MMPs.
  • RESULTS: Infiltration of BOECs into spheroids was blocked by low-dose EDTA.
  • Irradiation enhanced secretion of MMP-2 and, less so, of MMP-9 by tumor-stromal cells and tumor cells, and increased the amount of MMP-2 and -9 in subcutaneous LLC tumors.
  • [MeSH-major] Blood Cells / physiology. Cell Movement. Endothelial Cells / physiology. Matrix Metalloproteinase 2 / physiology. Matrix Metalloproteinase 9 / physiology. Spheroids, Cellular / physiology

  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595756.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 9G34HU7RV0 / Edetic Acid; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


69. Manolov I, Machulla HJ, Momekov G: Synthesis, physicochemical characterization and preliminary pharmacological in vitro evaluation of two novel cytotoxic benzophenone-linked 3,3-dimethyltriazenes. Pharmazie; 2006 Jun;61(6):511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the novel benzophenone-linked triazenes and of ten other 1-phenyl-3,3-dimethyl triazene derivatives as well as of the referent alkylating drug melphalan was assessed using the MTT-dye reduction assay.
  • A panel of human tumor cell lines was used: the chronic lymphoid leukemia SKW-3, the acute promyelocyte leukemia HL-60 and its multi-drug-resistant subline HL-60/Dox.
  • DNA-fragmentation analysis indicated that after 24 h treatment the novel benzophenone-linked triazenes induced programmed cell death in HL-60 cells.
  • [MeSH-minor] Cell Line. Chemistry, Physical. DNA Fragmentation / drug effects. DNA, Neoplasm / biosynthesis. HL-60 Cells. Humans. Models, Molecular. Physicochemical Phenomena. Structure-Activity Relationship. Tetrazolium Salts. Thiazoles

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826969.001).
  • [ISSN] 0031-7144
  • [Journal-full-title] Die Pharmazie
  • [ISO-abbreviation] Pharmazie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzophenones; 0 / DNA, Neoplasm; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Triazenes; 298-93-1 / thiazolyl blue
  •  go-up   go-down


70. Rankin JS, Orozco RE, Rodgers TL, Alfery DD, Glower DD: "Adjustable" artificial chordal replacement for repair of mitral valve prolapse. Ann Thorac Surg; 2006 Apr;81(4):1526-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gore & Associates Inc, Flagstaff, AZ) artificial chordal replacement and Carpentier ring annuloplasty (Edwards Lifesciences LLC, Irvine, CA), without leaflet resection.
  • Only 1 of 52 patients (1.9%) experienced late failure, and this patient was re-repaired with artificial chords.
  • Thus, "adjustable" artificial chordal replacement facilitates uniform repair of mitral valve prolapse with a low late failure rate.

  • MedlinePlus Health Information. consumer health - Mitral Valve Prolapse.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564319.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


71. Hwang HS, Min YS, Lee SC, Sun MK, Lim HS: Change of lip-line cant after 1-jaw orthognathic surgery in patients with mandibular asymmetry. Am J Orthod Dentofacial Orthop; 2009 Oct;136(4):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The purpose of this study was to investigate the change of lip-line cant (LLC) after 1-jaw orthognathic surgery in mandibular asymmetry patients.
  • LLC was measured in the preoperative and postoperative frontal photographs, and its change was correlated with various craniofacial measurements obtained from preoperative and postoperative frontal cephalograms and maxillofacial 3-dimensional computed tomography images.
  • RESULTS: Although these subjects had 2.4 degrees of LLC on average before surgery, LLC improved to 0.5 degrees after surgery, and the change (1.9 degrees ) was statistically significant.
  • In the correlation analysis, preoperative LLC showed positive correlations with menton deviation and mandibular anterior occlusal plane cant.
  • In the correlation analysis of LLC change, it had positive correlations with preoperative LLC and mandibular anterior occlusal plane cant and preoperative and postoperative change of menton deviation.
  • CONCLUSIONS: These results suggest that LLC is present with chin deviation, even without significant maxillary canting, and can be improved considerably by 1-jaw surgery alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815160.001).
  • [ISSN] 1097-6752
  • [Journal-full-title] American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
  • [ISO-abbreviation] Am J Orthod Dentofacial Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Lindhagen E, Nissle S, Leoni L, Elliott G, Chao Q, Larsson R, Aleskog A: R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother Pharmacol; 2007 Sep;60(4):545-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
  • OBJECTIVE: SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac, and has anti-tumour activity in chronic lymphocytic leukaemia (CLL).
  • The current study was performed to investigate and quantify the cytotoxic potentiating effects resulting from a combination of either SDX-101, SDX-308 or SDX-309 with standard cytotoxic agents used in the CLL treatment today.
  • METHODS: The lymphoma cell line U937-gtb was used, together with primary tumour cells isolated from seven CLL patients.
  • RESULTS: Most combinations were additive, which could be of clinical benefit since SDX-101 has been shown to be well tolerated.
  • At the 70% effect level, synergy was observed between SDX-308 and chlorambucil in U937-gtb cells and in two-third of the CLL samples.
  • Since chlorambucil is the most important drug in CLL therapy today and SDX-308 is presently targeted as the lead clinical candidate, this combination would be interesting for further studies.
  • Vincristine and SDX-309 were synergistic in two-fourth of CLL samples.
  • CONCLUSIONS: To conclude, the non-COX-inhibiting etodolac-derivatives SDX-101, SDX-308 and SDX-309 are potential candidates for combination treatment of CLL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Etodolac / pharmacology. Heterocyclic Compounds, 3-Ring / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Chlorambucil / administration & dosage. Doxorubicin / administration & dosage. Drug Synergism. Female. Humans. Lymphoma / drug therapy. Male. Middle Aged. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17186240.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Heterocyclic Compounds, 3-Ring; 0 / SDX 308; 0 / SDX 309; 18D0SL7309 / Chlorambucil; 2M36281008 / Etodolac; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


73. Collins SA, Buhles A, Scallan MF, Harrison PT, O'Hanlon DM, O'Sullivan GC, Tangney M: AAV2-mediated in vivo immune gene therapy of solid tumours. Genet Vaccines Ther; 2010;8:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immune-competent Balb/C or C57 mice bearing subcutaneous JBS fibrosarcoma or Lewis Lung Carcinoma (LLC) tumour xenografts respectively were treated by intra-tumoural administration of AAV2 vector encoding the immune up-regulating cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) and the co-stimulatory molecule B7-1 to subcutaneous tumours, either alone or in combination with intra-muscular (IM) delivery of AAV2 vector encoding Nk4 14 days prior to tumour induction.
  • Cured animals were re-challenged with tumourigenic doses of the original tumour type.
  • In vivo cytotoxicity assays were used to investigate establishment of cell-mediated responses in treated animals.
  • RESULTS: AAV2-mediated GM-CSF, B7-1 treatment resulted in a significant reduction in tumour growth and an increase in survival in both tumour models.
  • Cured animals were resistant to re-challenge, and induction of T cell mediated anti-tumour responses were demonstrated.
  • CONCLUSIONS: Overall, this study demonstrates the potential for in vivo AAV2 mediated immune gene therapy, and provides data on the inter-relationship between tumour vasculature and immune cell recruitment.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tissue Antigens. 2003 Mar;61(3):211-9 [12694570.001]
  • [Cites] Crit Rev Oncol Hematol. 1999 Feb;29(3):209-48 [10226727.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2442-50 [16489051.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):939-49 [18245558.001]
  • [Cites] Gene Ther. 2008 Jun;15(11):808-16 [18385765.001]
  • [Cites] Curr Gene Ther. 2008 Apr;8(2):66-78 [18393828.001]
  • [Cites] Genet Vaccines Ther. 2009;7:5 [19272140.001]
  • [Cites] Neuromolecular Med. 2009;11(1):43-52 [19306089.001]
  • [Cites] J Cell Biol. 1996 May;133(3):709-18 [8636243.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13110-5 [8662798.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Oct 29;239(3):639-44 [9367820.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1181-94 [11002212.001]
  • [Cites] Clin Experiment Ophthalmol. 2000 Oct;28(5):382-6 [11097287.001]
  • [Cites] Cell. 1992 Dec 24;71(7):1093-102 [1335364.001]
  • [Cites] Cancer Gene Ther. 2006 Dec;13(12):1061-71 [16874363.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5031-5 [2164219.001]
  • [Cites] Nat Immun Cell Growth Regul. 1990;9(3):165-72 [2370876.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2560-6 [2580624.001]
  • [Cites] CA Cancer J Clin. 1972 Jul-Aug;22(4):226-9 [4625047.001]
  • [Cites] J Exp Med. 1983 Mar 1;157(3):1040-52 [6187879.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):750-2 [6333639.001]
  • [Cites] J Immunol. 1993 Apr 15;150(8 Pt 1):3161-9 [7682233.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):1-6 [9450538.001]
  • [Cites] Cell Growth Differ. 1998 May;9(5):355-65 [9607557.001]
  • [Cites] Nat Med. 1999 Jan;5(1):56-63 [9883840.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1204-11 [11466335.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):719-25 [11857345.001]
  • [Cites] Cancer Sci. 2003 Apr;94(4):321-7 [12824898.001]
  • [Cites] Ernst Schering Res Found Workshop. 2003;(43):107-14 [12894454.001]
  • [Cites] Int J Cardiol. 2003 Aug;90(2-3):229-38 [12957756.001]
  • [Cites] J Immunol. 1961 Feb;86:228-39 [13785862.001]
  • [Cites] Dis Esophagus. 2003;16(3):218-23 [14641313.001]
  • [Cites] Gene Ther. 2004 Mar;11(6):534-43 [14999225.001]
  • [Cites] Eur J Immunol. 2004 Oct;34(10):2635-41 [15368278.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):316-27 [15950947.001]
  • [Cites] Cancer Gene Ther. 2005 Dec;12(12):913-25 [15962012.001]
  • [Cites] Gene Ther. 2005 Oct;12 Suppl 1:S159-69 [16231050.001]
  • [Cites] Cancer Immunol Immunother. 2006 Nov;55(11):1443-50 [16612593.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):523-32 [7507508.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1205-14 [7511683.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6477-83 [7527298.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1857-65 [7583565.001]
  • [Cites] Cancer Gene Ther. 1996 May-Jun;3(3):202-14 [8725885.001]
  • [Cites] Gene Ther. 1997 Mar;4(3):181-8 [9135731.001]
  • [Cites] Ciba Found Symp. 1997;212:119-30; discussion 130-2, 148-54 [9524767.001]
  • [Cites] Nat Med. 1998 May;4(5 Suppl):525-31 [9585204.001]
  • [Cites] Hum Gene Ther. 1999 Jan 20;10(2):201-13 [10022545.001]
  • [Cites] Nat Biotechnol. 1999 Feb;17(2):181-6 [10052356.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3906-10 [10097136.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):257-61 [10700178.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1317-26 [10942373.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 29;279(3):846-52 [11162438.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):604-8 [11406663.001]
  • [Cites] Hum Gene Ther. 2001 Oct 10;12(15):1907-16 [11589832.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):185-93 [11900993.001]
  • [Cites] J Virol. 2002 Dec;76(24):12900-7 [12438615.001]
  • [Cites] Nat Med. 2008 Jan;14(1):28-36 [18157142.001]
  • [Cites] Nature. 2008 May 15;453(7193):410-4 [18418378.001]
  • [Cites] Ultrasound Med Biol. 2010 Mar;36(3):430-40 [20133039.001]
  • [Cites] Cancer Gene Ther. 2010 Jul;17(7):501-11 [20186173.001]
  • [Cites] Postgrad Med. 2010 May;122(3):166-80 [20463426.001]
  • [Cites] Gene Ther. 2010 Aug;17(8):1042-51 [20596059.001]
  • [Cites] Trends Cell Biol. 1998 Oct;8(10):404-10 [9789329.001]
  • [Cites] Kidney Int. 2004 Aug;66(2):586-90 [15253710.001]
  • (PMID = 21172020.001).
  • [ISSN] 1479-0556
  • [Journal-full-title] Genetic vaccines and therapy
  • [ISO-abbreviation] Genet Vaccines Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3016353
  •  go-up   go-down


74. Küçköztaş MF, Ozgünes N, Yazici S: [Investigation of the relationship between hepatitis c virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis c patients]. Mikrobiyol Bul; 2010 Jan;44(1):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of the relationship between hepatitis c virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis c patients].
  • The objective of this retrospective study was to determine the distribution of HCV genotypes in patients with chronic hepatitis C infection at our region and to investigate the relation between genotypes and serum alanine aminotransferase (ALT) and HCV-RNA levels.
  • Serum samples from 52 patients (26 females, 26 males; mean age: 51.07 +/- 13.13 years) with chronic HCV infection were analyzed in this study.
  • Viral genotypes were determined by using the Versant HCV genotype assay (LiPA) 2.0 system (Bayer HealthCare LLC, USA) according to the manufacturer's instructions.
  • The mean age of the patients infected with genotype 1 (51.4 +/- 12.6 years) we e statistically significantly higher than the mean age of the patients infected with type 2 and 3 (37.8 +/- 12.3 years), (p = 0.023).
  • [MeSH-major] Alanine Transaminase / blood. Hepacivirus / genetics. Hepatitis C, Chronic / enzymology. Hepatitis C, Chronic / virology. RNA, Viral / blood

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455406.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / RNA, Viral; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


75. Kano R, Sato E, Okamura T, Watanabe S, Hasegawa A: Expression of Bcl-2 in feline lymphoma cell lines. Vet Clin Pathol; 2008 Mar;37(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bcl-2 in feline lymphoma cell lines.
  • Bcl-2 has been shown to repress cell death triggered by a diverse array of stimuli, including chemotherapy and gamma irradiation.
  • OBJECTIVE: The purpose of this study was to determine feline Bcl-2 expression level in feline lymphoma cells using an immunoblot assay with anti-human and anti-canine Bcl-2 monoclonal antibodies.
  • An immunoblot assay using the monoclonal antibodies was carried out to determine the level of feline Bcl-2 expression in lymphoma and lymphocytic leukemia cell lines.
  • RESULTS: The recombinant feline Bcl-2 protein produced in E. coli had a molecular weight of about 26 kDa and was detected by immunoblot assay by using anti-human Bcl-2 mouse monoclonal antibody.
  • Feline Bcl-2 expression was high in lymphoma cell lines (FL-74-UDC-1 and FT-1) and low in the cell line from peripheral blood mononuclear cells from a healthy cat (FeTJ-1) but not low in freshly isolated peripheral blood mononuclear cells from a healthy cat.
  • CONCLUSIONS: These results confirm the expression of Bcl-2 in T-cell lymphoma cell lines and indicate that it is suitable to detect feline Bcl-2 using an immunoblot assay.
  • Pending further evaluation, Bcl-2 expression might be useful in the differential diagnosis of feline tumors.


81. Kreitman RJ, Pastan I: Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets; 2006 Oct;7(10):1301-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunotoxins, composed of protein toxins connected to cell binding ligands including monoclonal antibodies and growth factors, have been developed for several decades to target hematologic malignancies.
  • Plant toxins, particularly ricin, are useful for chemically conjugating to monoclonal antibodies, and have shown clinical activity in several types of lymphoma and leukemia.
  • Their dose is generally limited by vascular leak syndrome.
  • Denileukin diftitox has shown efficacy in cutaneous T-cell lymphoma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.
  • Recombinant immunotoxin BL22 is an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin; it induces complete remissions in a high percentage of patients with chemoresistant hairy cell leukemia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17073592.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunotoxins
  • [Number-of-references] 235
  •  go-up   go-down


82. Kokhaei P, Palma M, Mellstedt H, Choudhury A: Biology and treatment of chronic lymphocytic leukemia. Ann Oncol; 2005;16 Suppl 2:ii113-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and treatment of chronic lymphocytic leukemia.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958440.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Number-of-references] 90
  •  go-up   go-down


83. Reuters I, Weber M, Schulze-Lohoff E: Rho/Rho kinase pathway regulates maintenance of the differentiated tubular epithelial cell phenotype on laminin-1. Nephron Physiol; 2006;104(2):p95-p106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rho/Rho kinase pathway regulates maintenance of the differentiated tubular epithelial cell phenotype on laminin-1.
  • BACKGROUND: Maintenance of a polarized tubular epithelium by appropriate intracellular signaling and extracellular matrix is critical both in normal renal function as well as in acute and chronic tubular injury.
  • We examined the hypothesis that maintenance of a differentiated epithelial phenotype on the basement membrane glycoprotein laminin-1 is controlled by the Rho/Rho kinase pathway.
  • METHODS: Using the tubular epithelial cell lines LLC-PK1 and MDCK which were cultured on laminin-1 vs. collagen IV, we analyzed cell morphology and motility (cohort migration assay) as well as expression of differentiation and dedifferentiation markers (immunofluorescence microscopy).
  • RESULTS: Cohort migration of LLC-PK1 cells was significantly slowed down on laminin-1 (10.7 +/- 2.2 m.u. (migratory units)) compared with collagen IV (16.6 +/- 2.3 m.u.
  • In parallel to the increased migratory activity, inhibition of the Rho/Rho kinase pathway resulted in a more mesenchymal phenotype of LLC-PK1 cells on laminin-1 with increased formation of lamellopodia and filopodia, distinct loss of focal contacts and stress fibers, upregulation of the dedifferentiation marker vimentin, and loss of cell-cell contacts with translocation of beta-catenin from the adherens junctions to the cytosol and nucleus.
  • Similarly, cohort migration of MDCK cells was retarded on laminin-1 when compared with collagen IV, and addition of the Rho kinase inhibitor Y27632 resulted in enhanced motility and a change in cell morphology.
  • CONCLUSION: The study demonstrates that the Rho/Rho kinase pathway is required to maintain a non-migratory epithelial phenotype of cultured renal tubular LLC-PK1 and MDCK cells on the basement membrane glycoprotein laminin-1.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Line. Cell Movement. Dogs. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Phenotype. Signal Transduction / drug effects. Signal Transduction / physiology. Swine. rho-Associated Kinases

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16847378.001).
  • [ISSN] 1660-2137
  • [Journal-full-title] Nephron. Physiology
  • [ISO-abbreviation] Nephron Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Laminin; 0 / laminin 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / rho-Associated Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


84. Virgin F, Zhang S, Schuster D, Azbell C, Fortenberry J, Sorscher EJ, Woodworth BA: The bioflavonoid compound, sinupret, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope; 2010 May;120(5):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Dehydration of airway surface liquid (ASL) disrupts normal mucociliary clearance in sinonasal epithelium leading to chronic rhinosinusitis.
  • Abnormal chloride (Cl(-)) transport is one mechanism that contributes to this disorder, as demonstrated by the disease cystic fibrosis.
  • Sinupret (Bionorica, LLC, San Clemente, CA), a combination of naturally occurring bioflavonoids, is a widely used treatment for respiratory ailments in Europe.
  • METHODS: Well characterized murine nasal septal epithelial (MNSE) cultures, and murine nasal potential difference (NPD) techniques were used to evaluate the effects of Sinupret on Cl(-) secretion.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422703.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chloride Channels; 0 / Chlorides; 0 / Flavonoids; 0 / Plant Extracts; 1F7A44V6OU / Colforsin; 77321-52-9 / Sinupret
  •  go-up   go-down


85. Biebinger R, Zimmermann MB, Al-Hooti SN, Al-Hamed N, Al-Salem E, Zafar T, Kabir Y, Al-Obaid I, Petry N, Hurrell RF: Efficacy of wheat-based biscuits fortified with microcapsules containing ferrous sulfate and potassium iodate or a new hydrogen-reduced elemental iron: a randomised, double-blind, controlled trial in Kuwaiti women. Br J Nutr; 2009 Nov;102(9):1362-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first objective of the study was to measure the efficacy in wheat flour of two newly developed Fe compounds, an H-reduced Fe powder (NutraFine RS; North America Höganäs High Alloys LLC, Johnstown, PA, USA) and small particle-sized (40 microm) encapsulated FeSO4.
  • A randomised, double-blind controlled intervention trial was conducted in Kuwaiti women (n 279; aged 18-35 years) with low body Fe stores (serum ferritin (SF) < 25 microg/l) randomly assigned to one of three groups (20 mg Fe as NutraFine RS, 10 mg Fe as encapsulated FeSO4 and 150 microg iodine, or no fortification Fe) who consumed wheat-based biscuits 5 d per week.
  • Relative to control, mean SF in the encapsulated FeSO4 group increased by 88 % (P < 0.001) and body Fe stores increased from - 0.96 to 2.24 mg/kg body weight (P < 0.001), while NutraFine RS did not significantly increase SF or body Fe stores.
  • The median urinary iodine concentration increased from 140 to 213 microg/l (P < 0.01).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. FERROUS SULFATE .
  • Hazardous Substances Data Bank. POTASSIUM IODATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653920.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Capsules; 0 / Ferrous Compounds; 0 / Hemoglobins; 0 / Iodates; 0 / Iron, Dietary; 0 / Potassium Compounds; 0 / Transferrin; 39R4TAN1VT / ferrous sulfate; E1UOL152H7 / Iron; I139E44NHL / potassium iodate
  •  go-up   go-down


86. Chen Z, Wang Y, Ratia K, Mesecar AD, Wilkinson KD, Baker SC: Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J Virol; 2007 Jun;81(11):6007-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human coronavirus NL63 (HCoV-NL63), a common human respiratory pathogen, is associated with both upper and lower respiratory tract disease in children and adults.
  • We generated polyclonal antisera directed against two of the predicted replicase nonstructural proteins (nsp3 and nsp4) and detected replicase proteins from HCoV-NL63-infected LLC-MK2 cells by immunofluorescence, immunoprecipitation, and Western blot assays.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2004 Jun;78(11):5957-65 [15140993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7 [15226499.001]
  • [Cites] Nucleic Acids Res. 2004;32(14):e115 [15304544.001]
  • [Cites] J Virol. 2004 Sep;78(18):9977-86 [15331731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1967 Apr;57(4):933-40 [5231356.001]
  • [Cites] J Virol. 1999 Apr;73(4):2658-66 [10074111.001]
  • [Cites] J Virol. 1999 Jul;73(7):5957-69 [10364348.001]
  • [Cites] J Virol. 2004 Dec;78(24):13600-12 [15564471.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1374-8 [15531891.001]
  • [Cites] Curr Top Microbiol Immunol. 2005;287:57-94 [15609509.001]
  • [Cites] J Virol. 2005 Jan;79(2):884-95 [15613317.001]
  • [Cites] J Infect Dis. 2005 Feb 15;191(4):503-6 [15655772.001]
  • [Cites] J Med Virol. 2005 Mar;75(3):463-5 [15648061.001]
  • [Cites] J Med Virol. 2005 Mar;75(3):455-62 [15648064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5 [15695582.001]
  • [Cites] J Virol. 2005 Apr;79(7):4550-1 [15767458.001]
  • [Cites] Clin Infect Dis. 2005 Jun 15;40(12):1721-9 [15909257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93 [15897467.001]
  • [Cites] Pediatr Infect Dis J. 2005 Jul;24(7):645-6 [15999010.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):599-609 [16064136.001]
  • [Cites] Emerg Infect Dis. 2005 Aug;11(8):1225-9 [16102311.001]
  • [Cites] Mol Cell. 2005 Aug 19;19(4):547-57 [16109378.001]
  • [Cites] PLoS Med. 2005 Aug;2(8):e240 [16104827.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4567-73 [16145108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5 [16169905.001]
  • [Cites] PLoS Biol. 2005 Oct;3(10):e324 [16128623.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] J Med Chem. 2005 Nov 3;48(22):6767-71 [16250632.001]
  • [Cites] Science. 2005 Oct 28;310(5748):676-9 [16195424.001]
  • [Cites] Structure. 2005 Nov;13(11):1665-75 [16271890.001]
  • [Cites] J Gen Virol. 1967 Apr;1(2):175-8 [4293939.001]
  • [Cites] Virology. 1992 Jul;189(1):274-84 [1318604.001]
  • [Cites] Virology. 1995 Jun 1;209(2):420-7 [7778277.001]
  • [Cites] Virology. 1995 Jun 1;209(2):489-97 [7539970.001]
  • [Cites] J Virol. 1997 Feb;71(2):900-9 [8995606.001]
  • [Cites] J Virol. 2000 Feb;74(4):1674-85 [10644337.001]
  • [Cites] J Virol. 2000 Sep;74(17):7911-21 [10933699.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33220-32 [11431476.001]
  • [Cites] Virology. 1995 Apr 1;208(1):1-8 [11831690.001]
  • [Cites] J Virol. 2002 Apr;76(8):3697-708 [11907209.001]
  • [Cites] J Virol. 2002 Jun;76(12):6323-31 [12021365.001]
  • [Cites] Chem Biol. 2002 Oct;9(10):1149-59 [12401499.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1319-25 [12711465.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):1967-76 [12690091.001]
  • [Cites] N Engl J Med. 2003 May 15;348(20):1953-66 [12690092.001]
  • [Cites] J Virol. 2003 Jul;77(13):7376-82 [12805436.001]
  • [Cites] J Gen Virol. 2003 Sep;84(Pt 9):2305-15 [12917450.001]
  • [Cites] J Virol. 2003 Oct;77(19):10515-27 [12970436.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:141-72 [14570567.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10136-41 [14699140.001]
  • [Cites] Emerg Infect Dis. 2004 Feb;10(2):320-6 [15030705.001]
  • [Cites] Nat Med. 2004 Apr;10(4):368-73 [15034574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6212-6 [15073334.001]
  • [Cites] Pediatr Infect Dis J. 2005 Nov;24(11):1015-7 [16282944.001]
  • [Cites] J Virol. 2005 Dec;79(24):15189-98 [16306590.001]
  • [Cites] J Virol. 2005 Dec;79(24):15199-208 [16306591.001]
  • [Cites] J Virol. 2005 Dec;79(24):15582-5 [16306630.001]
  • [Cites] Virol J. 2004;1:7 [15548333.001]
  • [Cites] Cell. 2005 Dec 2;123(5):773-86 [16325574.001]
  • [Cites] Proteins. 2006 Mar 15;62(3):760-75 [16358325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22 [16581910.001]
  • [Cites] J Virol. 2006 May;80(9):4211-9 [16611880.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8 [16723558.001]
  • [Cites] J Virol. 2006 Jun;80(12):5927-40 [16731931.001]
  • [Cites] J Virol. 2006 Jun;80(12):6003-12 [16731939.001]
  • [Cites] PLoS Pathog. 2005 Dec;1(4):e39 [16341254.001]
  • [Cites] Clin Infect Dis. 2006 Sep 1;43(5):585-92 [16886150.001]
  • [Cites] J Virol. 2006 Sep;80(17):8639-52 [16912312.001]
  • [Cites] J Virol. 2006 Dec;80(23):11610-20 [16971428.001]
  • (PMID = 17392370.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI060915; United States / NIAID NIH HHS / AI / P01-AI060915; United States / PHS HHS / / R01-A1045798
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ubiquitin; 0 / Viral Envelope Proteins; EC 3.4.22.- / 3C-like proteinase, Coronavirus; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.2 / Papain
  • [Other-IDs] NLM/ PMC1900296
  •  go-up   go-down


87. Lindhagen E, Norberg M, Kanduri M, Tobin G, Säisänen L, Aberg M, Gustafsson MG, Sundström C, Rosenquist R, Aleskog A: In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis. Eur J Haematol; 2009 Jul;83(1):22-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
  • BACKGROUND: There is a need for development of new drugs for treatment of B-cell chronic lymphocytic leukemia (CLL), especially for poor-prognostic subgroups resistant to conventional therapy.
  • OBJECTIVE: The in vitro antileukemic activity of 20 different anticancer agents was characterized in tumor cells from CLL, aiming at identifying agents active in poor-prognostic subgroups.
  • DESIGN AND METHODS: In tumor cells from 40 CLL patients and in peripheral blood mononuclear cells (PBMC) from three healthy controls, the activity of 20 substances was assessed using a non-clonogenic assay.
  • The CLL samples were characterized regarding genomic aberrations by interphase fluorescence in situ hybridization and immunoglobulin heavy-chain variable (IGHV) gene mutational status.
  • Most investigated drugs demonstrated similar activity in CLL cells from patients with unmutated and mutated IGHV genes as well as in CLL cells vs. PBMC.
  • Interestingly, prednisolone and rolipram displayed high CLL specificity, high activity in CLL cells with unmutated IGHV genes and retained the effect in several cases with 11q/17p deletion.
  • Further studies on prednisolone and rolipram revealed a synergy when these agents were combined in CLL cells, and suggested correlation between drug sensitivity and difference in downstream signaling.
  • CONCLUSION: Prednisolone and rolipram are interesting for further studies in CLL with inferior prognosis.
  • The study can also be considered a basis for future efforts to find drugs active in subsets of CLL patients that are resistant to conventional therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Prednisolone / pharmacology. Rolipram / pharmacology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245531.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Glucocorticoid; 9PHQ9Y1OLM / Prednisolone; K676NL63N7 / Rolipram
  •  go-up   go-down


88. Storey R, Gatt M, Bradford I: Mucosa associated lymphoid tissue lymphoma presenting within a solitary anti-mesenteric dilated segment of ileum: a case report. J Med Case Rep; 2009;3:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa associated lymphoid tissue lymphoma presenting within a solitary anti-mesenteric dilated segment of ileum: a case report.
  • INTRODUCTION: Mucosa associated lymphoid tissue (MALT) lymphoma is the third most common non-Hodgkin's lymphoma subtype.
  • Clinical presentation is often insidious as a low-grade lesion and disease tends to remain localised for a long period of time.
  • Histology of this segment demonstrated MALT lymphoma of the small bowel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2008;43(4):497-505 [18365916.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):529-33 [15729078.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):527-37 [9389360.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2486-92 [10561313.001]
  • [Cites] Arch Surg. 1994 Jun;129(6):659-61 [8204043.001]
  • [Cites] Cancer. 1983 Jan 1;51(1):80-91 [6336974.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • (PMID = 19126231.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2627909
  •  go-up   go-down


89. Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K: The evolving role of alemtuzumab in management of patients with CLL. Leukemia; 2005 Dec;19(12):2147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolving role of alemtuzumab in management of patients with CLL.
  • New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment.
  • Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL.
  • A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease.
  • The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Disease Management. Humans. Practice Guidelines as Topic. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239912.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Number-of-references] 24
  •  go-up   go-down


90. Giannopoulos K, Schmitt M, Własiuk P, Chen J, Bojarska-Junak A, Kowal M, Roliñski J, Dmoszyñska A: The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia; 2008 Jan;22(1):222-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. T-Lymphocytes, Regulatory / immunology. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / metabolism. Female. Forkhead Transcription Factors / metabolism. Humans. Interleukin-2 Receptor alpha Subunit / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657216.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Immunosuppressive Agents; 0 / Interleukin-2 Receptor alpha Subunit; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


91. Smolej L, Kasparová P: Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia. APMIS; 2008 Dec;116(12):1058-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia.
  • Angiogenesis is a potential prognostic factor in chronic lymphocytic leukemia (CLL).
  • Elevated circulating levels of angiogenic factors in CLL have been repeatedly reported.
  • Nevertheless, the issue of bone marrow neovascularization in CLL remains controversial, partly due to limited number of published studies, different methods of assessing microvessel density (MVD) and small patient cohorts.
  • Moreover, there are very scarce data regarding the relationship of marrow angiogenesis to prognostic markers in CLL.
  • To assess bone marrow MVD in CLL using two different monoclonal antibodies and a reproducible method of MVD quantification; 2.
  • MVD was higher using CD34 vs vWF antibody (p<0.0001).
  • However, no MVD differences were detected between CLL subgroups subdivided according to the above-mentioned prognostic factors.
  • No association of MVD with any prognostic factors was observed, possibly due to the limited patient cohort.
  • As the need for bone marrow trephine biopsies in CLL is significantly decreasing, a standardized method of neovascularization assessment is required to enable possible multicentre studies in order to conduct larger investigations and thereby shed more light on the real clinical significance of bone marrow angiogenesis in CLL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / blood supply. Bone Marrow / pathology. Endothelium, Vascular / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neovascularization, Pathologic / diagnosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133008.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / von Willebrand Factor
  •  go-up   go-down


92. Mankaï A, Buhé V, Hammadi M, Youinou P, Ghedira I, Berthou C, Bordron A: Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1. Ann N Y Acad Sci; 2009 Sep;1173:721-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
  • Lipopolysaccharide (LPS), CpG-containing phosphothioate oligonucleotides (CpG) and various cytokines impact chronic lymphocytic leukemia (CLL) B cells.
  • For example, they influence cell cycle entry, expression of co-receptors, and CD20.
  • Rituximab (RTX), for which CD20 molecule is the target, proved to be less efficient in CLL than in lymphoma.
  • This is accounted for by a lower CD20 level in the former than in the latter B lymphocytes.
  • CD20 transcription is mediated by four transcription factors, of which only purine-rich box-1 (PU.1) is reduced in CLL.
  • Thus, CpG accelerates the transcription of CD20 independently of PU.1, and thereby improves the efficacy of RTX in CLL.
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. B-Lymphocytes / drug effects. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Blotting, Western. Cell Line, Tumor. Cells, Cultured. Female. Flow Cytometry. Gene Expression Regulation, Leukemic / drug effects. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Rituximab. Transcription, Genetic / drug effects. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758221.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / CPG-oligonucleotide; 0 / Oligodeoxyribonucleotides; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


93. Masago M, Takaai M, Sakata J, Horie A, Ito T, Ishida K, Taguchi M, Hashimoto Y: Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells. Biol Pharm Bull; 2010;33(8):1407-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells.
  • The aim of the present study was to compare the membrane transport mechanisms of procainamide with those of quinidine using renal epithelial LLC-PK(1) and intestinal epithelial LS180 cells.
  • In LLC-PK(1) cells, the transcellular transport of 10 microM quinidine in the basolateral-to-apical direction was similar to that in the opposite direction, and 1 mM tetraethylammonium (TEA) did not affect the transcellular transport of the drug.
  • On the other hand, the transcellular transport of 10 microM TEA and procainamide in LLC-PK(1) cells was directional from the basolateral side to the apical side.
  • [MeSH-major] Anti-Arrhythmia Agents / pharmacokinetics. Cell Membrane / metabolism. Intestines / metabolism. Kidney / metabolism. Procainamide / pharmacokinetics. Quinidine / pharmacokinetics
  • [MeSH-minor] Animals. Biological Transport, Active. Caco-2 Cells. Cation Transport Proteins / metabolism. Drug Interactions. Epithelial Cells / metabolism. Humans. Hydrogen-Ion Concentration. LLC-PK1 Cells. Swine. Temperature. Tetraethylammonium / pharmacology

  • Hazardous Substances Data Bank. PROCAINAMIDE .
  • Hazardous Substances Data Bank. QUINIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686239.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Cation Transport Proteins; 66-40-0 / Tetraethylammonium; ITX08688JL / Quinidine; L39WTC366D / Procainamide
  •  go-up   go-down


94. Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu B, Gao J, Chen Z: Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology; 2008;82(2):148-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously reported that dihydroartemisinin is found to have a potent ability in influencing lymphatic endothelial cell migration and tube formation.
  • In this study, we investigated the effect of artemisinin on tumor growth, lymphangiogenesis, metastasis and survival in mouse Lewis lung carcinoma (LLC) models.
  • Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.
  • [MeSH-minor] Administration, Oral. Animals. Female. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Lymphangiogenesis / drug effects. Lymphatic Metastasis / prevention & control. Mice. Mice, Inbred C57BL. Neoplasm Metastasis / prevention & control. Survival Rate. p38 Mitogen-Activated Protein Kinases / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18667841.001).
  • [ISSN] 1423-0313
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Artemisinins; 0 / Vascular Endothelial Growth Factor C; 9RMU91N5K2 / artemisinine; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


95. Sleep 2009. Abstracts of the 23rd Annual Meeting of the Associated Professional Sleep Societies, LLC. June 6-11, 2009. Seattle, Washington, USA. Sleep; 2009;32 Suppl:A1-427
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleep 2009. Abstracts of the 23rd Annual Meeting of the Associated Professional Sleep Societies, LLC. June 6-11, 2009. Seattle, Washington, USA.

  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760817.001).
  • [ISSN] 0161-8105
  • [Journal-full-title] Sleep
  • [ISO-abbreviation] Sleep
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] United States
  •  go-up   go-down


96. Szmigielska-Kapłon A, Jesionek-Kupnicka D, Góra-Tybor J, Błonski JZ, Lech-Marańda E, Kordek R, Kasznicki M, Robak T: Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. Leuk Lymphoma; 2007 May;48(5):1042-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia.
  • [MeSH-major] Bone Marrow Cells / drug effects. Cladribine / administration & dosage. Cladribine / therapeutic use. Cyclophosphamide / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Mitoxantrone / administration & dosage. Neovascularization, Pathologic

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487753.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


97. Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R: U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res; 2010 Sep 1;16(17):4331-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
  • Food and Drug Administration (FDA) approval of ofatumumab (Arzerra, GlaxoSmithKline) for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
  • EXPERIMENTAL DESIGN: The FDA reviewed the results of a planned interim analysis of a single-arm trial, enrolling 154 patients with CLL refractory to fludarabine, and a supportive dose-finding, activity-estimating trial in 33 patients with CLL.
  • RESULTS: For regulatory purposes, the primary efficacy population consisted of 59 patients with CLL refractory to fludarabine and alemtuzumab.
  • CONCLUSIONS: On October 26, 2009, the FDA granted accelerated approval to ofatumumab for the treatment of patients with CLL refractory to fludarabine and alemtuzumab, on the basis of demonstration of durable tumor shrinkage.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Drug Approval / legislation & jurisprudence. Drug Resistance, Neoplasm / drug effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601446.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / ofatumumab; 3A189DH42V / alemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


98. Ohno H, Nishikori M, Maesako Y, Haga H: Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma. Int J Hematol; 2005 Dec;82(5):397-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.
  • The BCL3 gene was initially discovered through its involvement in a recurring translocation, t(14;19)(q32;q13), which is found in some patients with B-cell chronic lymphocytic leukemia (B-CLL).
  • Anaplastic large cell lymphoma (ALCL) is a subtype of aggressive non-Hodgkin's lymphoma that is characterized by expression of CD30 and the NPM/ALK chimeric protein, which is generated by t(2;5)(p23;q35).
  • We compared the gene expression profiles of ALCL with those of another CD30+ neoplasm, Hodgkin's disease (HD), and found that BCL3 is expressed at higher levels in ALCL than in HD.
  • A comparison by real-time polymerase chain reaction assay revealed that t(2;5)+ ALCL expresses a high level of BCL3 messenger RNA relative to the levels expressed in other hematologic tumors, and the level in ALCL is comparable to or even higher than that in t(14;19)+ B-CLL.
  • An immunohistochemical analysis of ALCL tumor tissues showed that the lymphoma cells exhibited strong nuclear staining by a monoclonal antibody against Bcl-3.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosomes, Human / genetics. Gene Expression Regulation, Leukemic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Transcription Factors

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 1;101(7):2789-96 [12456498.001]
  • [Cites] Nat Immunol. 2001 May;2(5):397-402 [11323692.001]
  • [Cites] J Pathol. 2003 Sep;201(1):75-82 [12950019.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):380-9 [9010112.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jan;1(3):247-55 [2083219.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Immunity. 1997 Apr;6(4):479-90 [9133427.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4307-12 [11110706.001]
  • [Cites] Genomics. 1994 Nov 1;24(1):120-6 [7896265.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):88-92 [14603446.001]
  • [Cites] Cancer Sci. 2005 Aug;96(8):487-97 [16108830.001]
  • [Cites] Int J Hematol. 1994 Apr;59(3):211-8 [8011990.001]
  • [Cites] Int J Hematol. 2000 Jul;72(1):110-1 [10979220.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Int J Hematol. 2003 Jan;77(1):37-47 [12568298.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):669-74 [8627180.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):353-64 [15093542.001]
  • [Cites] Cell. 1992 Feb 7;68(3):421-7 [1310894.001]
  • [Cites] Leukemia. 2004 Jan;18(1):11-7 [14574329.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):339-42 [1406939.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):527-35 [11485911.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1682-8 [15117990.001]
  • [Cites] Oncogene. 1998 May 7;16(18):2333-43 [9620550.001]
  • [Cites] Genes Dev. 1993 Jul;7(7B):1354-63 [8330739.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Sep;20(1):64-72 [9290956.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8293-301 [14678988.001]
  • [Cites] Leukemia. 1993 Dec;7(12):2057-63 [8255106.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3915-26 [8196632.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27657-62 [11356851.001]
  • [Cites] Cell. 1990 Mar 23;60(6):991-7 [2180580.001]
  • [Cites] Oncogene. 2000 Feb 24;19(9):1123-31 [10713699.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9257-60 [3122218.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1146-7 [12869493.001]
  • [Cites] Cell. 1993 Mar 12;72(5):729-39 [8453667.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6951-61 [9819383.001]
  • [Cites] Cell. 1992 Mar 20;68(6):1109-20 [1339305.001]
  • [Cites] Leuk Res. 2000 Nov;24(11):881-911 [11086173.001]
  • [Cites] Cell. 1996 Feb 23;84(4):551-62 [8598042.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6180-90 [11707390.001]
  • [Cites] Mol Cell. 2004 Oct 8;16(1):35-45 [15469820.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):813-6 [12153169.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):207-12 [10637266.001]
  • [Cites] Proteins. 1993 Dec;17(4):363-74 [8108379.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1413-26 [9135156.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2901-10 [9376569.001]
  • [Cites] Mol Pathol. 2003 Jun;56(3):156-61 [12782762.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3557-66 [8497270.001]
  • [Cites] Nature. 1990 Mar 1;344(6261):36-42 [2137557.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33132-9 [9407099.001]
  • [Cites] Int J Cancer. 1985 Sep 15;36(3):287-90 [3875568.001]
  • (PMID = 16533741.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 0 / proto-oncogene protein bcl-3
  • [Number-of-references] 59
  •  go-up   go-down


99. Rosati E, Sabatini R, Rampino G, De Falco F, Di Ianni M, Falzetti F, Fettucciari K, Bartoli A, Screpanti I, Marconi P: Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL. Blood; 2010 Oct 14;116(15):2713-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel targets for endoplasmic reticulum stress-induced apoptosis in B-CLL.
  • A better understanding of apoptotic signaling in B-chronic lymphocytic leukemia (B-CLL) cells may help to define new therapeutic strategies.
  • This study investigated endoplasmic reticulum (ER) stress signaling in spontaneous apoptosis of B-CLL cells and whether manipulating ER stress increases their apoptosis.
  • Results show that a novel ER stress-triggered caspase cascade, initiated by caspase-4 and involving caspase-8 and -3, plays an important role in spontaneous B-CLL cell apoptosis.
  • ER stress-induced apoptosis in B-CLL cells also involves CHOP/GADD153 up-regulation, increased JNK1/2 phosphorylation, and caspase-8-mediated cleavage of Bap31 to Bap20, known to propagate apoptotic signals from ER to mitochondria.
  • In ex vivo B-CLL cells, some apoptotic events associated with mitochondrial pathway also occur, including mitochondrial cytochrome c release and caspase-9 processing.
  • However, pharmacologic inhibition studies show that caspase-9 plays a minor role in B-CLL cell apoptosis.
  • ER stress also triggers survival signals in B-CLL cells by increasing BiP/GRP78 expression.
  • Manipulating ER signaling by siRNA down-regulation of BiP/GRP78 or treating B-CLL cells with 2 well-known ER stress-inducers, tunicamycin and thapsigargin, increases their apoptosis.
  • Overall, our findings show that ER triggers an essential pathway for B-CLL cell apoptosis and suggest that genetic and pharmacologic manipulation of ER signaling could represent an important therapeutic strategy.
  • [MeSH-major] Apoptosis / physiology. Endoplasmic Reticulum / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Caspases / metabolism. Down-Regulation. Gene Rearrangement, B-Lymphocyte. Heat-Shock Proteins / antagonists & inhibitors. Heat-Shock Proteins / genetics. Humans. In Vitro Techniques. Membrane Proteins / metabolism. Models, Biological. RNA, Small Interfering / genetics. Signal Transduction / drug effects. Stress, Physiological. Thapsigargin / pharmacology. Tunicamycin / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628148.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAP31 protein, human; 0 / Heat-Shock Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / molecular chaperone GRP78; 11089-65-9 / Tunicamycin; 67526-95-8 / Thapsigargin; EC 3.4.22.- / Caspases
  •  go-up   go-down


100. Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM, Chen Y, Jiang N, Moore JO, Gockerman JP, Diehl LF, Decastro CM, Potti A, Nevins JR: A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res; 2009 Nov 15;15(22):6947-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
  • PURPOSE: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course.
  • Several parameters have prognostic capabilities but are associated with altered response to therapy in only a small subset of patients.
  • Genomic signatures that reflect progressive disease and responses to chemotherapy or chemoimmunotherapy were created using cancer cell lines and patient leukemia cell samples.
  • We validated and applied these three signatures to independent clinical data from four cohorts, representing a total of 301 CLL patients.
  • RESULTS: A genomic signature of prognosis created from patient leukemic cell gene expression data coupled with clinical parameters significantly differentiated patients with stable disease from those with progressive disease in the training data set.
  • The progression signature was validated in two independent data sets, showing a capacity to accurately identify patients at risk for progressive disease.
  • In addition, genomic signatures that predict response to chlorambucil or pentostatin, cyclophosphamide, and rituximab were generated and could accurately distinguish responding and nonresponding CLL patients.
  • CONCLUSIONS: Thus, microarray analysis of CLL lymphocytes can be used to refine prognosis and predict response to different therapies.
  • These results have implications for standard and investigational therapeutics in CLL patients.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Leuk Res. 2008 Feb;32(2):225-33 [17675228.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1721-8 [11681413.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1215-9 [12149200.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2748-55 [12456497.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):346-61 [12651908.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Leuk Res. 2003 Sep;27(9):765-74 [12804633.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8431-6 [15152076.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):69-72 [15325098.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3937-49 [15459216.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):439-47 [8882957.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):460-71 [15686453.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Exp Hematol. 2005 Aug;33(8):883-93 [16038780.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):437-43 [16344317.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1774-82 [16932341.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Biostatistics. 2007 Jan;8(1):118-27 [16632515.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Mayo Clin Proc. 2007 Apr;82(4):449-53 [17418074.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4679-85 [17299097.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1984-91 [17611561.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12):1063-70 [17654680.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):474-80 [11251968.001]
  • (PMID = 19861443.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112952-01; United States / NCI NIH HHS / CA / U54 CA112952; United States / NCI NIH HHS / CA / 5U54 CA112952; United States / NCI NIH HHS / CA / U54 CA112952-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 18D0SL7309 / Chlorambucil; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS140337; NLM/ PMC2783430
  •  go-up   go-down